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Abstract 
Oxidative-stress-induced neuronal apoptosis has been implicated in the development of 
neurodegenerative diseases such as ischemic stroke. Pro-apoptotic proteins including Caspase 3 
and Bax are critical components of the apoptotic pathway. In this study we aimed to identify 
specific inhibitors of Caspase 3 and Bax. We isolated two single domain antibodies (sdAbs) 
against Caspase 3; one (VhhCasp31) capable of blocking Caspase 3 function in vitro and in vivo, 
and the other (VhhCasp32) acting oppositely. The genes and antibodies coded by them can be 
used as a platform for therapeutic development for neuroprotective or anti-cancer agents . 
We also screened a pharmacaphore library of small molecular weight compounds capable 
of binding to Bax and blocking function in the same manner as a specific anti-Bax sdAb inhibitor 
previously found by our group. We found "compound 22," which was capable of competitive 
binding to Bax and blocked Bax function in vitro and in vivo. 
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Chapter 1: Introduction 
1.1 Apoptosis 
Apoptosis, or programmed cell death, is a tightly regulated process of cell removal and 
plays a fundamental role in the maintenance of tissue homeostasis in the adult organism and the 
developing fetus (Fadeel et al., 2005). It is a necessary process that is crucial for not only the 
normal development of an organism, but in the removal of harmful or damaged cells. Apoptosis 
is an active, physiological process that is characterized by specific morphological and 
biochemical changes that distinguish it from necrotic or accidental cell death (Adhihetty et al, 
2003). Most of the recognizable events definitive of apoptosis were documented in the 1950's. 
Its role in embryonic development was understood then, but the importance of apoptosis in the 
daily maintenance of the adult organism was not recognized until the 1970's. Kerr et al. (1972) 
reported that the same type of cell death present during development also happens in mature 
organisms and continues throughout life. Additionally, they suggested that unlike necrotic cell 
death, where the cell is a passive victim, this form of cell death is active, meaning the cell 
expends energy toward its own destruction. They further proposed that inappropriate initiation 
or inhibition of apoptosis could contribute to many diseases such as neurodegeneration, and 
cancer (Kerr et al, 1972). 
1.2 Apoptosis vs. Necrosis 
Apoptosis occurs in response to conditions such as DNA damage, oxidative stress, 
deprivation of growth factors and stimulation of specific death receptors, and is characterized by 
cell shrinkage, membrane blebbing, and chromatin condensation (Pollack et al, 2001). Necrotic 
1 
cell death, on the other hand, is a passive, pathological form of cell death and occurs when a cell 
is severely injured, for example by oxygen deprivation or a physical stressor. It takes on 
morphological changes quite different from apoptotic cell death, including swelling of the cell, 
rupturing of the cell, leading to tissue inflammation and ultimately cell death (Pollack et al, 
2001). 
1.3 Apoptotic Pathways 
Apoptosis can be induced by two different signalling pathways: an external route, where 
external factors bind to membrane bound death receptors on the outside of the cell, and an 
internal route, where internal cellular occurrences lead to the release of specific death inducing 
factors from the mitochondria or the endoplasmic reticulum (ER) (Adhihetty et al, 2003). All 
apoptosis signalling pathways converge on a common pathway of cell destruction that involves 
activated caspases (Strasser et al, 2000). In most cell types, the morphological characteristics of 
apoptosis remain consistent, whether the extrinsic or intrinsic pathway is followed. 
1.3.1 Extrinsic: Receptor-mediated Apoptotic Pathway 
Apoptosis can be induced by the binding of ligands to either one or more of the 
extracellular receptors belonging to the tumour necrosis factor (TNFR) superfamily. Important 
ligands involved in this cell death pathway are the cytokine TNF-a and the Fas ligand (FasL). 
Activation of the appropriate receptors by these ligands ultimately leads to the activation of a 
family of proteases collectively referred to as caspases (Adhihetty et al, 2003). For example, 
binding of FasL to its receptor evokes oligomerization of Fas receptor and procaspase 8 
recruitment to the Fas-Associated Death Domain (FADD) (Hsu et al, 1996). This binding 
2 
recruits additional procaspase 8 molecules leading to formation of the Death-inducing Signalling 
Complex (DISC) which cleaves and activates Caspase 8 (Varadhachary et al., 2001). Upon 
activation, Caspase 8 can mediate the cleavage of Caspase 3, which when active, DNA 
fragmentation occurs and ultimately causes apoptosis. 
1.3.2 Intrinsic: Mitochondrial-mediated Apoptotic Pathway 
Mitochondria are involved in many processes that are imperative for cell survival 
including: energy production, calcium homeostasis, redox control, and certain metabolic and 
biosynthetic pathways (Bouchier-Hayes, et al, 2005). In addition, mitochondria frequently play 
an essential role in physiological cell death. Mitochondria are linked to several pathological 
conditions such as cancer, obesity, diabetes, ischemia/reperfusion injury, and neurodegenerative 
disorders such as Parkinson's Disease and Alzheimer's Disease (Kroemer et al., 2007). 
Most cell death in vertebrates proceeds via the mitochondrial intrinsic pathway of apoptosis 
(Green et al, 2004). The key event in the mitochondrial pathway of apoptosis is mitochondrial 
outer membrane permealization (MOMP) and the subsequent leakage of proapoptotic proteins 
from the mitochondrial intermembrane space (IMS) into the cytosol. This leads to cytosolic 
caspase activation, loss of inner mitochondrial membrane potential (A^m), cellular ATP 
depletion, and free radical production (Newmeyer et al, 2003). There are two principal 
hypotheses as to the mechanism of MOMP, one of which is that MOMP is regulated by the Bcl-2 
family of proteins; the other: MOMP is regulated by the permeability transition pore (PTP) 
(Bouchier-Hayes et al, 2005). The first model focuses on MOMP as a process that involves 
only the outer membrane of the mitochondria and requires members of the Bcl-2 family of 
proteins to either promote or prevent the formation of pores. In a study 
3 
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Figure 1.1 Extrinsic, Receptor-mediated Apoptotic Pathway 
Overview of the receptor-mediated apoptotic pathway: Ligands (such as FasL) bind to extracellular receptors of the 
TNFR superfamily (TRAIL, CD95L). Binding of FasL induces oligomerization of Fas receptor and procaspase 8 
recruitment to FADD. This binding recruits additional procaspase 8 molecules leading to the formation of the DISC 
with cleaves and activates Caspase 8. Upon activation, Caspase 8 can mediate the cleavage of Caspase 3, which 
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Figure 1.2 Intrinsic, mitochondrial-mediated apoptotic pathway 
Upon appropriate apoptotic stimuli, pro-apoptotic proteins such as Bax will translocate to the mitochondria causing 
MOMP and subsequent release of Cyt c. Cyt c interacts with Caspase 9 and Apaf-1 forming the Apoptosome which 
leads to the activation of Caspase 9. Caspase 9 in turn activates effector Caspase 3 leading to apoptosis. 
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study by Kuwana et al (2002) that used vesicles formed from isolated mitochondrial outer 
membranes (MOMs), showed that Bcl-2 family proteins can regulate the permeability of the 
MOM in the absence of the interior components of the mitochondria. In addition, many 
attributes of this process of membrane permealization could be reproduced using specific 
liposomes and recombinant Bcl-2 family proteins. However, a drawback of this cell-free system 
is that it probably does not represent the complete complexity of the permealization process as it 
happens in vivo. Other proteins of the MOM could be involved in either modulatng or 
potentiating the function of Bax and Bak proapoptotic Bcl-2 family proteins. Moreover, the 
release of specific IMS proteins in the cytosol could be influenced by the anchoring of these Bcl-
2 proteins to internal mitochondrial components or involvement of the mitochondrial cristae 
(Scorrano et al, 2002). 
The second prominent model for MOMP is based on an event known as mitochondrial 
permeability transition pore (PTP) formation (Kroemer et al, 2007). PTP formation allows for 
rapid permealization of the mitochondrial inner membrane (MIM) to solutes smaller than 
1.5kDa. The PTP complex is known as a "megapore" that is thought to span the contact sites 
between the inner and outer mitochondrial membranes and is presumed to be composed of at 
least 3 main proteins. These three proteins are the voltage-dependent anion channel (VDAC) in 
the outer membrane, the soluble matrix protein cylcophilin D (Cyp D), and the adenine 
nucleotide translocase (ANT) in the inner membrane (Zamzani et al, 2001). 
9-1-
During normal Ca homeostasis, the PTP exists in a state of low conductance, however 
when excess Ca + is released from the ER and overloads the mitochondria, the pore transitions to 
a high-conductance state. This switch to high-conductance is irreversible and dependent on the 
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saturation of Ca binding sites on the PTP (Ichas et al, 1998). This high-conductance 
conformation of the PTP, which can be due to pro-apoptotic stimuli such as oxidative stress and 
ischemia/reperfusion (Crompton et al, 1999), allows for the free diffusion of water and ions 
between the cytosol and the matrix, causing collapse of A^m, swelling of the mitochondrial 
matrix, and uncoupling of oxidative phosphorylation. This ultimately results in the rupture of the 
MOM and subsequent release of IMS proteins (Bouchier-Hayes et al, 2005). Rupturing of the 
MOM can also occur via Bax/Bak-mediated permealization and VDAC-mediated 
permealization. The expression of either Bax or Bak is required for MOMP, in several different 
models of apoptosis induction (Wei, et al, 2001). Upon reception of apoptotic signals, Bax 
inserts into the OM (Wolter, et al, 1997), where it is thought to form supramolecular openings, 
alone or in association with other pro-apoptotic members such as Bak or tBid. Bax and Bak have 
been shown function in coordination with PTP proteins, such as VDAC and ANT, to cause 
MOMP (DeGiorgi et al, 2002; Precht et al, 2005; Weaver et al, 2005; Wigdal et al, 2002). 
There has been much evidence that VDAC may exhibit some degree of specificity in the 
mitochondrial import/export of molecules (e.g. ATP, Ca2+, and other ions). In 2000, Tsujimoto 
et al showed that recombinant Bax and Bak accelerate the opening of VDAC in reconstituted 
proteoliposomes. This group presented evidence that VDACl-deficent mitochondria isolated 
from a mutant yeast strain failed to exhibit the Bax/Bak-induced Â Pm loss and Cytochrome c 
(Cyt c) release that was observed with VDAC 1-expressing control mitochondria. Lastly, it has 
been shown that microinjection of neutralizing anti-VDAC antibodies into cells prevented Bax-
induced Cyt c release and AYm loss (Shimizu, et al, 2001). 
The release of IMS proteins is a pivotal component of both the caspase-dependent and 
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Figure 1.3A Mechanistic Model of MOMP 
The first model focuses on MOMP as a process that involves only the outer membrane of the mitochondria 
and requires members of the Bcl-2 family of proteins, such as Bax, to either promote or prevent the formation of 
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Figure 1.4: Model of MOMP 
The second prominent model for MOMP is based on an event known as mitochondrial permeability 
transition pore (PTP) formation. The PTP complex is known as a "megapore" that is thought to span the inner and 
outer mitochondrial membranes and is presumed to be composed of at least 3 main proteins. These three proteins 
are the voltage-dependent anion channel (VDAC) in the outer membrane, the soluble matrix protein cylcophilin D 
(Cyp D), and the adenine nucleotide translocase (ANT) in the inner membrane. An influx of H20 and other ions are 
believed to cause matrix swelling and MOM rupture leading to the release of Cyt c. 
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pathway, executioner caspases are cleaved and activated by the initiator Caspase 9. Caspase 9 is 
activated by multidimerization on the adapter molecule Apoptosis-Protease-Activating-Factor 1 
(APAF-1) within a multidomain complex containing Cyt c called the apoptosome. APAF-1 pre-
exists in the cytosol as a monomer, and its activation is dependent on the presence of Cyt c and 
ATP/ADP (Cain et al, 2002). The release of Cyt c, which normally resides only in the IMS 
where it shuttles electrons in the respiratory chain, is required for the formation of the 
apoptosome. Activation of Caspase 9 leads to the activation of Caspase 3, which translocates to 
the nucleus to induce DNA fragmentation through the activation of DNases and deactivation of 
DNA repair machinery (Pollack et al, 2001). Thus, MOMP is a crucial event responsible for 
caspase activation in the intrinsic pathway. MOMP can even commit a cell to die when caspases 
are not activated. This pathway, known as caspase-independent death, (Chipuk et al, 2005, 
Kroemer et al, 2005) occurs when there is irreversible loss of mitochondrial function as well as 
mitochondrial release of caspase-independent death effectors, such as apoptosis inducing factor 
(AIF) (Susin, et al, 1999) and Endonuclease G (EndoG) (Li et al, 2001). AIF and Endo G 
initiate apoptosis by directly translocating to the nucleus without the involvement of caspases 
(Adihihetty etal, 2003). 
1.4 The Bcl-2 Family of Proteins 
The Bcl-2 family of proteins is comprised of over a dozen proteins that have been 
classified into three functional groups. These groups include both pro- and anti-apoptotic 
members, each containing one or more Bcl-2 homology domains (BH1 through BH4) (Adams et 
al, 1998). Members of the first group are anti-apoptotic and have all four Bcl-2 homology (BH) 
domains (BH1-BH4). These proteins also have a C-terminal hydrophobic tail that allows them 
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to localize to the outer surface of the mitochondrial membrane. This group includes Bcl-2, Bcl-
xL, and Mcl-1. The members of the second group are similar in structure to the members of the 
first group; however they are pro-apoptotic and lack the BH4 domain. This group includes Bax, 
Bak, and Bok. Members of the third group, that are pro-apoptotic, are BH3-only proteins which 
include Bid, Bad, Puma, and several others (Hengartner, 2000). 
Cell survival is determined by the balance between anti-apoptotic Bcl-2 family proteins 
such as Bcl-2, Bcl-xL, and Mcl-1, and pro-apoptotic proteins such as Bax, Bak, and Bok proteins. 
Bax and Bak are effectors of MOMP, whereas their anti-apoptotic counterparts act as inhibitors 
of this permealization process, not as effectors of an independent survival mechanism (in regards 
to MOMP) (Kroemer et al, 2007). In addition, MOMP mediated by Bax and Bak may be 
triggered by secondary modulator proteins, such as the BH3-only proteins Bim and Bid (Adams 
et al, 1998) Pro- and anti-apoptotic Bcl-2 family members can heterodimerize and titrate one 
another's function, suggesting that their relative concentration may act as a rheostat for the cell 
suicide program (Oltavi, et al, 1993). Studies using mutagenesis models have established that 
the BH1, BH2, and BH3 domains strongly influence homo- and hetero-dimerization within this 
family of proteins (Yin et al, 1994). In the event of over-expression of pro-apoptotic members 
of the Bcl-2 family such as Bax, apoptosis is accelerated, as observed in tissues where cell death 
occurs as part of the normal maturation process (e.g. epidermis) (Oltvai, Z et al, 1993). 
Conversely, over-expression of Bcl-2 (or related anti-apoptotic members) leads to 
heterodimerization (with Bax) and inhibition of death induction (Oltvai, Z et al, 1993). 
Bax, in particular, exists predominantly in the cytosol prior to apoptotic induction. Early 
during apoptosis, Bax translocates from the cytosol to the mitochondria where it participates in 
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mitochondrial disruption and the release of Cyt c (Hsu et al., 1997 Wolter et al, 1997; Green et 
al, 1998). There are four different isoforms of Bax which are derived from the alternative gene 
splicing of bax: Bax y (5kDa), P (24kDa), 6 (16kDa), and a (21kDa). Of the four isoforms, only 
Bax a and P contain the BH3 domain necessary for pro-apoptotic function, and only a, the most 
prominent isoform of Bax, has the C-terminal transmembrane domain required for insertion into 
the mitochondrial membrane that leads to MOMP (Oltavai et al, 1993). By altering the insertion 
of Bax into the mitochondrial membrane, apoptosis can also be modulated. Several studies have 
examined the effects of alterations in the C-terminal transmembrane region of Bax on 
mitochondrial targeting and induction of apoptosis (Goping et al, 1998; Gross et al, 1998; 
Neuchushtan et al, 1999). 
It has been reported that the full-length cDNA of human Bax fused to GFP is diffuse in 
the cytosol in healthy cells, and becomes punctuate and localized in the mitochondria in cells 
undergoing apoptosis (Wolter et al, 1997). Comparatively, Bax that is lacking its 21 amino acid 
hydrophobic C-terminal tail is found to be diffuse in the cytosol of healthy cells in addition to 
cells treated with staurosporine, a kinase inhibitor used extensively to trigger apoptosis (Weil et 
al, 1996). In a study performed by Neuchuhstan et al. in 1999, it was noted that Serl84 is most 
important in the regulation of the subcellular location of Bax. Mutation of Serl84 can freeze 
Bax in either the cytosol or the mitochondria depending on the amino acid substitution. Altering 
Serl84 to Val or deleting it entirely causes Bax to localize with the mitochondria of healthy 
cells, whereas changing Serl 84 to His, Glu, Lys, or Asp results in a cytosolic location in healthy 
cells (Neuchashtan et al, 1999). The role of Serl 84 has been further characterized by Xin et al. 
in 2006 where they identified the effect of nicotine induced post-translational phosphorylation of 
Bax at Ser 184 by protein kinase Akt. This post-translational modification has been shown to 
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inactivate Bax specifically in lung cancer cells. Additionally, protein phosphatase 2A (PP2A) 
was found to be an active regulator in this particular cell type, working to both dephosphorylate 
Bax and interfere with Bax-Bcl-2 heterodimerization, allowing Bax to homodimerize and 
permeate the mitochondria inducing apoptosis (Xin, M et al, 2006). 
In 2000, the solution structure of Bax was determined using NMR by Suzuki et al. It has 
been reported by this group (in addition to others) that the structure of Bax consists of nine a 
helices and its overall fold closely resembles that of anti-apoptotic protein Bcl-xL (Muchmore et 
al, 1996) which has eight amphipathic a helices clustered around one central hydrophobic helix 
(a5). Earlier studies have shown that a portion of helix al is hidden in the cytosolic form of Bax 
but becomes accessible to antibody binding after membrane insertion during apoptosis 
(Nechushtan et al., 1999). In addition, helix a2 encompasses the BH3 domain that is the 
functionally important region for interaction between members of the Bcl-2 family. Particularly, 
this helix in Bcl-xL and the Bcl-XL-Bak complex is packed closer to the hydrophobic core of the 
protein than it is in Bax. This may be what makes the protein pro- or anti-apoptotic: the relative 
exposure of the BH3 domain. A portion of the C-terminal hydrophobic region of Bax, the 
putative transmembrane domain, contains helix a9. The helix a9 of Bax is located in the 
hydrophobic pocket in a similar manner to the way a Bak BH3 peptide binds to the BC1-XL, 
although the directional sense of the peptide is opposite to that of the C-terminal helix of Bax 
(Suzuki et al, 2000). This demonstrates that although pro- and anti-apoptotic members of the 
Bcl-2 family both contain BH3 domains, the orientation and exposure of the domain to outside 
binding partners differs, allowing for the unique properties of members of the Bcl-2 family. 
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Studies utilizing various deletion mutants of Bax have demonstrated that Bax uses its 
BH3 domain (helix a2) for homodimerization and heterodimerization with other members of the 
Bcl-2 family (both pro- and anti-apoptotic), as a mutation in only this region rendered the protein 
unable to dimerize (Zha, H et al, 1995). Specifically, Bax is understood to bind to itself and 
other Bcl-2 members in a parallel tail-to-tail fashion using the BH3 domain. However, the anti-
apoptotic Bcl-2 proteins dimerize to each other using an anti-parallel head-to-tail conformation 
that involves the BH4 domains of one protein and the BH1 and BH2 domains of the second. 
When heterodimerizing with a pro-apoptotic binding partner, BH1 and BH2 domains of the anti-
apoptotic protein interact with the BH3 domain of the pro-apoptotic partner (Yin et al, 1994). 
Additionally, the Bax C-terminus (helix a9) has been shown to bind to its own BH3 binding 
pocket when present in the cytosol. This binding conformation would prevent dimer formation 
in the cytosol. It is unlikely that another Bcl-2 family member alone could compete with the C-
terminal helix of Bax for binding to its BH3 pocket. This suggests that dimerization via this 
pocket cannot occur in the cytosol without the presence of an energy-driven process that would 
disengage helix a9 from helix a2 (Suzuki et al, 2000). 
1.5 The Role of Caspases in Apoptosis 
Caspases have been strongly implicated to play an essential role in apoptosis (Lee et al, 
2000a). Caspases are cysteine aspartic acid proteases and in humans, they are synthesized as 
zymogens awaiting appropriate apoptotic stimuli, and upon stimulation, are protealitically 
cleaved to become activated. They are manufactured in the cell as single-chain precursors, 
where activation occurs by cleavage at the conserved ASP297 residue and a conformational 
change occurs, bringing it into the correct alignment for catalysis (Salvesen et al, 1999). 
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There are eleven human caspases that have been identified thus far (Humke et al, 1998) 
and they can play an essential role in apoptosis as initiator proteins, such as Caspase 8/9, 
activating downstream caspases. As well, caspases can act as executioner or effector proteases 
(Caspase 3/7) resulting in DNA damage and apoptosis. Sequence analysis and x-ray 
crystallography data have suggested that all caspases share a common structure (Cohen, 1997; 
Humke et al, 1998; Nicholson et al, 1997; Shimin et al, 1998; Van de Craen, et al, 1997). 
Each zymogen contains an N-terminal prodomain, a large subunit containing the active site 
cysteine within a conserved QACXG motif, and a small C-terminal subunit. An aspartate 
cleavage site separates the prodomain from the large subunit, and an interdomain linker that 
contains one or two aspartate cleavage sites separates the large and small subunits (Wolf et al, 
1999). Activation of the caspase accompanies the cleavage of the interdomain linker, usually 
resulting in the removal of the prodomain. The active caspase enzyme functions as a tetramer, 
consisting of two large/small subunit heterodimers. The heterodimers each contain an active site 
comprised of residues from both the small and large subunits (Mittl, et al, 1997; Walker et al, 
1994; Wilson et al, 1994). Since caspases exist as latent zymogens, the question has often been 
raised as to how they are activated. Current evidence suggests that the activation may proceed 
via auto-activation, transactivation, or proteolysis by other proteinases (Wolfed al, 1999). 
Importantly, Caspase 3, one of the main executioner caspases of apoptosis, has been 
found to be activated in nearly every model of apoptosis and its substrates include many proteins 
involved in cell maintenance and/or repair (Nicholson et al, 1997). For example, 
oligonucleosome fragmentation (DNA laddering) is a characteristic feature of apoptosis and is 
mediated by caspase-activated deoxyribonuclease (CAD), whose activation is modulated by the 
caspase-3-mediated cleavage of the CAD inhibitor ICAD (Enari et al, 1998). 
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As previously mentioned, pathways to Caspase 3 activation have been identified that are 
either dependent on or independent of mitochondrial Cyt c release. It has been shown that 
microinjection of cytochrome c causes apoptosis of HeLa and Hek293 cells, but not of Caspase 3 
defective MCF-7 (breast cancer) cells (Li, et al, 1997). Once Caspase 3 is activated, 
downstream substrates of cell death are cleaved irrespective of the involvement of Cyt c (Cryns 
et al, 1998; Nicholson et al, 1997; Reed et al, 1997). However, Caspase 3 may also amplify 
the upstream death cascade, including cytochrome c release, by cleaving Bcl-2 and BC1-XL, thus 
destroying the anti-apoptotic function of these proteins and releasing C-terminal fragments that 
are pro-apoptotic (Porter et al, 1999; Wolf et al, 1999). 
However, Caspase 3 is important for survival, as Caspase 3-knockout mice are born at a 
low frequency and die after only a few weeks (Kuida et al, 1996; Woo et al, 1998). The mice 
that are born possess skull defects with masses of supernumary cells that represent the failure of 
programmed cell death during development of the brain. Additionally, insufficient apoptosis due 
to caspase inactivation may promote oncogenesis by allowing cell accumulation (Martin et al, 
1996). Alternatively, caspase over-reactivity promotes excessive cellular suicide, which may be 
the basis for such neurodegenerative disorders as Huntington's Disease (HD) and AD 
(Wellington et al, 1998; Wolozin et al, 1996). On the molecular level, an increase in 
expression/activity of caspases, adapters, apoptotic sensors, or diminished expression/activity of 
caspase inhibitors could increase caspase activity. 
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1.6 Oxidative Stress in Mammalian Cells: Mitochondria are the major site of ROS 
Production 
Reactive oxygen species (ROS) such as superoxide anion (O2 .), hydrogen and organic 
peroxides, are produced in all aerobic cells as by-products of several metabolic reactions and in 
response to various stimuli (Fleury et al, 2001; Fridovich, 1998). In particular, ROS are 
produced in the mitochondria by the partial reduction of molecular oxygen, where they play an 
important role as regulatory mediators in signalling processes (Droge, 2002). However, ER and 
the nuclear membrane also contain electron transport chains that can lose electrons and produce 
superoxide radicals. Physiologically, the activity of the respiratory chain leads to the generation 
of semi-quinines, a potential source of ROS (Papa, et al, 1997). The respiratory chain produces 
ROS at complex I (NADH/ubiquinone oxidoreductase) and complex III (ubiquinol/cytochrome c 
oxido-reductase). In particular, the ubiquinone site at complex III appears to be the major site of 
mitochondrial ROS production as this site catalyzes the conversion of molecular oxygen to the 
superoxide anion radical (O2.) by the transfer of one electron to molecular oxygen (Papa et 
al, 1997; Turrens et al, 1985). Moreover, the inhibition of the respiratory chain, due to the lack 
of oxygen or an inhibitor such as cyanide or antimycin A, increases the ubisemiquinone free 
radical level in the normal catalytic mechanism of complex III (Turrens et al, 1985). The 
superoxide anion can generate other potent types of ROS such as H2O2. A reductive homolytic 
cleavage of H202 yields the highly oxidative and cytotoxic hydroxyl radical (OH'). This highly 
reactive radical is accountable for most of the oxidative damage leading to necrosis (Halliwell et 
al, 1990). Alternatively, mitochondrial superoxide may react with nitric oxide to produce 
peroxynitrite, a powerful oxidant, which causes irreversible inhibition of mitochondrial 
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respiration and damage to mitochondrial components such as complexes I, II, IV, and V, creatine 
kinase, membranes, mtDNA, and superoxide dismutase (SOD) (Groves, 1999). Nitric oxide 
(NO) can promote or inhibit apoptosis depending on the cell type (Chung et al, 2001). 
Cells have multiple sites for ROS production and few mechanisms for degradation. ROS 
are also involved in such physiological processes as mediation in signal transduction pathways, 
activation of proteins like tyrosine kinase or mitogen-activated protein kinases (MAPKs). 
Current evidence suggests that different stimuli use ROS as signalling messengers to activate 
such transcription factors as AP-1 and NF-KB, and to induce gene expression (Pinkus et al., 
1996). 
An excess of ROS in the mitochondria causes oxidative stress, leading to enhanced 
activity of the antioxidant defence system and mitochondrial damage. Stresses, such as 
dysfunctional complex I, chemical poisoning, and ischemia followed by reperfusion, can subject 
tissues and cells to oxidative damage (Fleury et al, 2001). The main targets of ROS in 
mitochondria are the protein components of the membranes and the polyunsaturated fatty acids. 
Oxidants increase the release of calcium from the mitochondria, thus stimulating enzymes that 
are calcium-dependent, such as proteases, nucleases, and phospholipases. Due to the absence of 
DNA-protecting proteins in the mitochondria, the low efficiency repair mechanism, and the 
proximity of the respiration chain, mtDNA is a prime target for ROS (Shoji et al, 1995). 
For prevention of oxidative damage, mammalian cells have established a complex 
antioxidant defence system that is composed of non-enzymatic antioxidants such as glutathione 
and thioredoxine, along with enzymatic components such as catalase and SOD (Sies, 1991). 
Importantly, mitochondria posses an antioxidant system of SOD, NADH, and a complete 
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glutathione redox system formed by glutathione reductase, reduced glutathione (GSH), and 
glutathione peroxidase. This system allows for the reduction of oxidants, such as hydroperoxide 
(Reed, 1990). When free radical generation exceeds the capacity of the cell to detoxify them, 
protein and DNA damage can occur, leading to cell death. The ability of oxidative stress to 
initiate necrotic cell death has been widely documented (Halliwell et al, 1989); the possible 
involvement of ROS as signalling molecules in physiological cell death is a more recent concept. 
The first evidence suggesting the involvement of mitochondrial ROS in apoptotic cell death 
arose from the study of the TNF-a-induced cytotoxicity (Droge, 2002; Fernandez-Checa, 2003; 
Lanchaster et al, 1989; Margaill et al, 2005; Schulze-Osthoff et al, 1992). Notably, ROS 
accumulation was found to precede alterations in the mitochondrial membrane, nuclear 
condensation, and other characteristic apoptotic events. Studies that utilized antioxidants 
displayed that ROS act upstream of mitochondrial membrane depolarization (Sidoti-de Fraisse et 
al, 1998), Bax relocalization, Cyt c release, executioner caspase activation, and nuclear 
fragmentation. 
1.7 Oxidative Stress and Neurodegenerative Disease 
Acute and chronic neurodegenerative diseases are illnesses associated with high 
morbidity and mortality which have few or no effective options available for their treatment 
(Friedlander, 2003). One of the characteristics of many neurodegenerative diseases (which 
include, but are not limited to stroke, brain trauma, spinal cord injury, Alzheimer's Disease, 
Parkinson's Disease, amyotrophic lateral sclerosis, and Huntington's Disease) is neuronal cell 
death (Yuan et al, 2000). Normally, apoptotic cell death plays a crucial role in the development 
of the nervous system, with both anti- and pro-apoptotic modulators being prominently featured 
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Single domain antibody libraries have been constructed from the RNA of naive llama 
lymphocytes, which contain phages that display a specific sdAb on their surface and harbour the 
gene for this sdAb inside. Through a technique called panning, a specific sdAb along with its 
gene can be identified for a particular antigen of interest (Tanha et al., 2002). Importantly, the 
gene itself can be transfected inside cells as intrabodies in order to understand the effects of the 
sdAb in vivo. 
1.9 Intrabodies as Therapeutic Agents in Neurodegenerative Disease 
Intrabodies, or intracellular antibodies, are known as antibody fragments that are 
expressed intracellularly and directed to specific subcellular compartments (Kontermann, 2004). 
For this study, the intrabodies are the product of the transfected genes for the sdAbs that had a 
high affinity for Caspase 3. The concept of using intrabodies as therapeutic agents is based on 
the ability of the intrabody to: directly inhibit the function of the subcellular molecule (i.e. by 
sterically preventing interactions of the target protein with its protein partners); to restore 
function to an intracellular molecule; or to divert the target molecule from its normal intracellular 
location or purpose (Miller et al, 2005). In contrast to the direct administration of a drug, this 
approach allows the cell to express the sdAb gene and use its own machinery to produce the 
therapeutic agent and since the intrabodies are produced only in cells, this yields the advantages 
of safety and efficacy (Kontermann, 2004). 
Many neurodegenerative diseases such as Parkinson's Disease, Alzheimer's Disease, and 
stroke are mediated by abnormal intracellular protein expression, with intrabodies being a 
potential therapy for these diseases. The use of intrabodies may allow for the identification or 
validation of novel drug targets. As well, intrabodies are small in size, stable, specific, and may 
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prove less immunogenic than other protein therapies, important factors when treating 
neurodegenerative disease (Miller et al, 2005). 
In the last few years much research has been done to discover ways in which these 
intrabodies can be used as therapeutics. Recently, expression of p21, erbB-2, huntingtin, and 
MHC have all been individually downregulated using intrabodies (Arafat et al, 2000; Crochet et 
al, 1998; Lecerf et al, 2001; and Mhashilkar et al, 2002). Additionally, intrabodies have been 
shown to have potent antiviral potential, particularly through targeting of the intracellular action 
of such mandatory HIV viral proteins as Vif, Tat, and Rev (Conclaves et al., 2002). 
Investigation has also been carried out on the ability of intrabodies to inhibit aggregation 
of proteins found in cases of Huntington's Disease. Work by Colby et al. in 2004, found a single 
domain intrabody capable of inhibiting toxic huntingtin (htt) aggregation in the brain. In this 
study, the group utilized a variable light chain intrabody against htt that prevented aggregation 
and rescued neurons from toxicity in a neuronal model (SHSY-5Y cells) of Huntington's Disease 
(Colby etal, 2004). 
Intrabodies have also been utilized in manipulating the subcellular location of proteins 
such as pro-apoptotic Caspase 7. In a study by Zhu et al. in 1999, a single chain scFv intrabody 
was genetically fused with known intracellular protein trafficking signals. They were able to 
direct Caspase 7 from its normal location in the cytosol to either the nuclei or peroxisomes, thus 
affecting its apoptotic function (Zhu et al, 1999). 
The use of intrabodies to obtain phenotypic knockouts has several advantages over other 
knockout models like RNA interference (RNAi) in understanding cellular functions and 
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developing therapeutic agents. RNAi has the risk of non-specific effects by binding to alternate 
mRNA sites, whereas intrabodies are tailored to manipulate specific antigens within the cell. It 
was reported by Persengiev et al. in 2004 that through use of a typical 21bp siRNA (small 
interfering RNA) on cells, over 1000 genes involved in many unrelated cellular functions were 
affected (Persengiev et al, 2004). Moreover, many target complexes have multiple 
binding/interacting sites, and thus the modulation of the gene may lead to alteration of various 
functions, which may not be desired. Therefore, by developing and screening intrabodies that 
can bind to a specific site on multidomain complexes, this risk could be eliminated (Heng et al, 
2005). 
Work by our group has demonstrated the use of single domain intrabodies against Bax 
protein to block its function under oxidative stress conditions, thereby inhibiting apoptosis 
(Gueorguieva et al, 2006). These anti-Bax sdAbs can be used to study the role of Bax in 
oxidative-stress-induced-apoptosis intracellularly, and also as a platform from which to develop 
novel, small molecule therapies for neurodegenerative diseases involving oxidative stress. 
1.10 Screening Pharmacaphore Libraries: Use of Small Molecule Inhibitors of Apoptosis 
Small-molecule inhibitors are useful tools for the elucidation of many mechanisms of 
cellular processes (Schreiber et al, 1998). They are more stable than peptide inhibitors and are 
often cell-permeable, thus making it easy to compare in vivo the activity of the analogues that 
have a variety of activities in vitro. Particularly, the use of small-molecule inhibitors of protein-
protein interactions is extremely useful, as most intracellular pathways are controlled primarily 
by protein-protein interactions. Previously, most of the available cell-permeable inhibitors were 
mechanism-based enzyme inhibitors, and there were very few examples of small molecule-
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inhibitors of protein-protein interactions acting inside cells. Presently, many researchers are 
focusing their studies in the field of inhibition of protein interaction making it an exciting new 
area of interest, especially when considering interactions of the Bcl-2 family of proteins (Young 
etal, 1998). 
There are two general approaches by which small-molecule, non-peptide modulators of 
protein-protein interaction can be identified. A number of studies have employed these 
approaches to identify modulators of protein-protein interactions with potential therapeutic use 
for the treatment of diseases such as cancer and degeneration (Berg et ah, 2003). One such 
approach is through screening combinatorial pharmacaphore libraries for modulators of protein-
protein interaction. This approach does not require prior knowledge of the dimerization, 
although such information would be helpful when establishing assays for high-throughput 
screening of large chemical libraries. 
A second approach involves in silico screening of chemical databases in order to 
preselect molecules most likely to bind to a region of protein-protein interaction, and thereby 
modulate it. The rate of success is much higher than that obtained screening untargeted libraries; 
however, this approach requires detailed structural information about the interface of the protein 
dimer from NMR spectroscopy or X-ray crystallography. Moreover, the plasticity of protein-
protein interfaces makes the prediction of interactions, specifically those contributing to 
modulation, an even more challenging endeavour (Delano et ai, 2000). 
Several studies have utilized these approaches to identify small molecule modulators of 
members of the Bcl-2 family in hopes of developing potential therapeutics for cancer and 
neurodegeneration. For example, Becattini et al. in 2006 identified two chemical fragments 
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using an NMR-based approach (structure-activity relationships by interligand NOE) that bind 
weakly to the surface of tBid, a pro-apoptotic protein. Covalent linkage of the two fragments led 
to a much higher affinity bidentate derivative. Through both in vitro and in vivo assays they 
were able to demonstrate that the compounds prevent tBid translocation to the mitochondrial 
membrane and subsequent release of pro-apoptotic stimuli, inhibiting neuronal apoptosis 
(Becattini et al, 2006). 
Two other studies performed independently by Wang et al. in 2000, and Oltersdorf et al. 
in 2005, examined the ability of two separate organic compounds to bind to anti-apoptotic Bcl-2 
family proteins (Bcl-2 in the first study, and Bcl-2, BC1-XL, and Bcl-w in the second study) and 
induce apoptosis in tumour cells. Wang et al. examined through a computer binding strategy a 
small molecular weight compound, HA 14-1, that was predicted to be a ligand of a Bcl-2 surface 
pocket. In vitro studies displayed the direct interaction of HA 14-1 with this Bcl-2 surface pocket 
that is required for Bcl-2 biological function. HA 14-1 was also shown to effectively induce 
apoptosis in human acute myeloid leukemia (HL-60) cells overexpressing Bcl-2 protein (Wang 
et al, 2000). 
In the study performed by Olsterdorf et al, by utilizing NMR-based screening, parallel 
synthesis, and structure-based design, they found ABT-737, a small-molecule inhibitor of the 
anti-apoptotic proteins Bcl-2, Bcl-XL, and Bcl-w. Importantly, ABT-737 was found to have an 
affinity of two to three orders of magnitude higher than previously reported compounds 
(Becattini et al, 2004; Enyedy et al, 2001, and Wang et al, 2000). ABT-737 displayed the 
ability to induce apoptosis in cells from lymphoma and small-cell lung cancer carcinoma lines, 
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as well as primary-patient derived cells. In animal models, ABT-737 caused regression of 
established tumours and improved survival of the animal (Oltersdorf et al, 2005). 
Importantly, in a study performed by Degterev et al. in 2001, a commercially available 
library consisting of 16,320 chemicals was screened and three compounds BH3I-1 and BH3I-1' 
(close homologues) and an unrelated BH3I-2 were identified as inhibitors of the Bcl-xi/Bak-
BH3 interaction. NMR spectroscopy experiments demonstrated that the inhibitor compounds 
targeted the BH3-binding pocket of BC1-XL. The Bcl-xi/Bak-BH3 inhibitors restored the function 
of pro-apoptotic Bcl-2 family members in cell culture, and allowed previously resistant cancer 
cells to undergo apoptosis (Degterev et al, 2001). 
In our present study, the screening of pharmacaphore libraries for small molecular weight 
compounds that can bind to pro-apoptotic Bax and block its function was performed. We 
screened 34 small molecules from the same commercial library as Degterev et al (2001). One of 
these compounds is the BH3I-1 inhibitor itself, and the remaining 33 are derivatives of BH3I-1. 
Since all the members of the Bcl-2 family have a BH3 domain, and BH3I-1 disrupts the BH3 
domain of Bak from interacting with the hydrophobic cleft formed by the BH1, BH2 and BH3 
domains of BC1-XL, we proposed that perhaps one of these derivatives of BH3I-1 could 
preferentially bind to the BH3 domain of Bax, thus blocking its function/interaction with other 
proteins/mitochondria required for apoptotic induction (Degterev et al, 2001). 
1.11 Objectives 
In this two-part study we plan examine two pro-apoptotic proteins, Bax and Caspase 3, 
which can become excessively activated during oxidative-stress-induced apoptosis and play 
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pivotal roles in the death of neurons in neurodegeneration. In order to prevent this inappropriate 
induction of apoptosis, we plan to investigate the use of single domain antibodies (sdAbs or 
VHH) to inhibit the activity of Caspase 3, and small molecular weight organic compounds to 
inhibit the activity of Bax. 
Part 1: Inhibition of Caspase 3 activity 
The objectives of this study are as follows: 
1) To isolate and purify recombinant Caspase 3 from a culture of E. coli harbouring the gene 
for said protein. 
2) In collaboration with Dr. J. Tanha (NRC-IBS) to isolate Caspase 3 specific VHHs (sdAbs) 
by panning a llama phage display library and immobilized recombinant Caspase 3. 
3) To evaluate and characterize the ability of isolated Caspase 3 specific VHHS to modulate 
the activity of active Caspase 3 in vitro by utilizing a Caspase 3 activity assay. 
4) Lastly, to express the anti-Caspase 3 VHH genes inside human neuroblastoma cells 
(SHSY-5Y) through transfection, and study their ability to block oxidative stress-
induced-apoptosis. 
Part 2: Inhibition of Bax activity 
The objectives of this study are as follows: 
1) To isolate and purify recombinant Bax from a culture of E.coli harbouring the gene for 
said protein 
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2) In collaboration with Dr. J. Tanha (NRC-IBS), to fluorescently label anti-Bax sdAb5.2 
with cy5.5. This sdAb was previously found by Gueorguieva et al. in 2006 to confer the 
greatest resistance to oxidative-stress-induced apoptosis out of six screened sdAbs, and 
thus will be used in subsequent competitive binding assays. 
3) To utilize the cy5.5-labelled sdAb5.2 in competitive binding assays with immobilized 
recombinant Bax to screen a 34-member pharmacaphore library in evaluating whether 
these small molecular weight compounds can competitively bind to Bax. 
4) To evaluate in vitro the ability of the 34 compounds to lower the level of Bax-induced 
ROS in isolated mitochondria. 
5) To study the efficacy of selected compounds to block oxidative stress induced apoptosis 
in neuroblastoma, differentiated neuroblastoma, and NT-2 neuronal precursor cells. 
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Chapter 2 Materials and Instrumentation 
2.1 Chemicals and Supplies 
Most of the chemicals were purchased from Sigma Aldrich Chemical Company, 
Mississauga, ON, Canada. These chemicals include: Bacto yeast extract, Bacto tryptone, 
chlormphenicol, kanamycin, arabinose, IPTG, lysozyme, DNase, imidazole, MSO4, BSA, 
CHAPS, HEPES, MgCl2, H202, HRP, EDTA, EGTA, TRIS-HC1, Triton X-100, PHPA, PMSF 
succinate, trypsin-EDTA, KC1, mannitol, Tween, CaCl2, Annexin V-FITC, collagen, retinoic 
acid, and horse radish peroxidise-conjugated anti-mouse and anti-rabbit. 
NaH2P04, Na2HP04, DMSO, NaOH, NaCI, DTT, NaHC03, and sucrose were purchased 
from BDH, Toronto Canada. Protein assay reagent, protein marker, and acrylamide were 
obtained from Bio Rad, Ontario Canada. Glycine was purchased from EM Sciences, NJ, USA. 
Hoescht and Annexin V red were obtained from Molecular Probes, Eugene OR, USA. BDNF 
was obtained from Alomone Labs, Israel. 
Monoclonal anti-Bax and polyclonal anti-Caspase 3 and VDAC antibodies were all 
purchased from Sigma, Mississauga, ON. ChemiGlow West kit was purchased from Alpha 
Innotech Corporation, San Leonardo CA, USA. JC-1 kit was purchased from Cell Technology, 
Mountain View. CA, USA. Fugene 6 Transfection Reagent was purchased from Hoffmann-La 
Roche Ltd., Mississauga, ON, Canada and DEVD-AFC was obtained from MP-Biomedicals, 
Aurora, OH. 
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2.2 Cell Culture Supplies 
2.2.1 Cell Lines 
Human Neuroblastoma (SHSY-5Y) cells and neuronally-committed human 
teratocarcinoma (NT-2) cells were purchased from the American Type Culture Collection 
(ATCC), Manassas, VA, USA. 
2.2.2 Media 
Dulbecco's Modified Eagles Medium (DMEM) F12 HAM was purchased from Sigma 
Chemical Company, Mississauga, ON, Canada. L-Glutamine, Gentamycin, and Fetal Bovine 
Serum (FBS) were all purchased from Gibco BRL, VWR, Mississauga, ON, Canada. 
2.3 Instrumentation 
Fluorescence measurements were conducted in the SpectraMan Gemini XS multiplate 
reader (Molecular Devices, Sunnyvale CA USA). Cell culture was performed under sterile 
conditions in the class-II type A/B3 Biosafety cabinet (Nuaire). Cells were maintained in an 
incubator with 5% CO2 which used a HEPA filter (Thermo Forma). A Dounce homogenizer 
from Kontes Glass Company (NJ, USA) was used along with, freezer vials (VWR) and 
Eppendorf pipettes (Fisher Scientific). Phase contrast and fluorescent pictures were taken using 
an inverted stage fluorescent microscope (Leica DM 1RB, Germany) and another fluorescence 
microscope (Zeiss Axioskope 2 Mot plus, Gottingen, Germany) and fluorescence pictures were 
taken using a camera (Qlmaging, Gottingen, Germany). The images were processed using 
Improvision OpenLab v3.1.2, and Adobe Photoshop v8.0. Cell culture supplies included culture 
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flasks and dishes, pipettes, freezer vials, and tubes were obtained from Sarstedt Inc, Montreal, 
Quebec, Canada. 
A pH Meter model 8100 and buffer solutions (VWR) and an Adventurer balance 
(OHAUS) were used. Absorbance was measured by the Genesys 10 UV-Vis Spectrophotometer 
(Thermo Scientific, Waltham, MA, USA) and centrifugation was done using low speed 
centrifuge (Jouan) and DESAGA (Sarstedt-Gruppe). Vortex Jr. Mixer (Scientific Industries Inc), 
a heating block (Gibco BRL, VWR, Canada) and a rocking platform (VWR) were all used as 
well. 
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Chapter 3 Methods 
3.1 Isolation of Recombinant Bax and Caspase 3 
3.1.1 Expression of Recombinant Bax and Caspase 3 
A culture of E.coli transformed with the gene for Bax protein harbouring a His6-tag was 
obtained from Bruno Antonsson and used to inoculate a lOOmL of a 1L stock of L.B. media 
(lOg NaCl, lOg Bacto Tryptone, 5g Bacto Yeast Extract, 1L ddH20, and 30ug/mL 
Chlormphenicol). This was incubated on a shaker overnight at 37°C and then transferred to the 
remaining 900mL stock L.B. media. The culture was then placed in the 37°C shaker for an 
additional 3-4 hours, following which the OD280 was ensured to be between 0.40-0.75 using 
UV/VIS before induction with Arabinose (lg/L). This final culture was then incubated overnight 
on the shaker at 37°C before centrifugation at 12,500 x g for 15 minutes at 4°C. The supernatant 
was discarded and the pellets were stored at -20°C overnight for subsequent purification. A 
culture of E. coli transformed with the gene for Caspase 3 also containing a His6-tag (ATCC, 
Manassas, Va) was used to inoculate an L.B. media stock in a similar manner as the Bax E.coli 
with the following differences: instead of 30fj,g/mL Chloramphenicol, 40|o.g/mL of Kanamycin 
was used in the LB. media, and instead of lg/L of Arabinose, 0.24g/L of IPTG was used for 
induction. 
3.1.2 Purification of Recombinant Bax and Caspase 3 
Prior to purification, the E. coli pellets expressing either Bax or Caspase 3 were 
resuspended in a lysis/loading buffer (0.02M phosphate buffer (NaH2PC»4, Na2HP04), lOOug/mL 
lysozyme, 5ug/mL DNase, 350^ig/mL PMSF, 1% Triton X-100, and 0.05M imidazole) and 
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incubated on ice for 45min. Following the incubation, the resupended pellets were sonicated at 
4°C, centrifuged at 12,500 x g for 15min at 4°C and the supernatant was kept as it contained the 
protein of interest (either Bax or Caspase 3). Both cultures of Bax and Caspase 3 E. coli were 
purified using a Hi-Trap nickel chelating affinity column (GE Healthcare, Baie d'Urfe, QC, 
Canada). The column was prepared by running 20mL of ddF^O, followed by 4mL of a 0.1 M 
Nickel Sulfate solution, 20mL of ddr^O, and lastly 30mL of the loading buffer to equilibrate the 
column. The supernatant was then loaded onto the column and washed with the loading buffer 
to elute any non-specific proteins that may be bound to the column. The fractions were collected 
(5mL/fraction) and the absorbance was determined using UV/VIS. This absorbance was 
monitored and once the values significantly decreased indicating the removal of the loosely-
bound non-specific proteins, lOmL of the elution buffer (0.02 Phosphate buffer, 0.5M imidazole) 
was added. Fractions were collected in lmL increments and the absorbance was read again to 
determine the fractions that contained the highest amounts of desired protein (Bax or Caspase 3). 
These fractions were placed in dialysis tubing overnight followed by lyopholization and 
resuspension in 5mL of ddH20 and EDTA to a final concentration of 0.05mM. The purity of 
Bax or Caspase 3 was confirmed via Western Blot (described below). 
3.2 Protein Estimation 
The total protein estimation was done using the BioRad protein assay reagent and 
performed on isolated Caspase 3and the sdAbs to determine their concentrations. 2.5uL of the 
sample was added to 797.5uL of ddH20 and 200uL of the BioRad protein assay dye reagent to 
obtain a final volume of lmL in a plastic cuvette. The samples were then vortexed and incubated 
at room temperature for 10 minutes, following which the absorbance readings were taken using a 
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UV-Visible spectrophotometer at 595nm. A standard curve using 1 .Omg/mL BSA solution was 
developed and the various unknown concentrations of the proteins could be determined from the 
standard curve. 
3.3 Isolation of sdAbs (VHHs) against recombinant Caspase 3 Through Panning a 
Llama Phage Display Library 
The following work was carried out by Dr.J.Tanha and associates at the National 
Research Council of Ottawa (Institute for Biological Sciences) (NRC-IBS). 
A llama VHH phage display library described previously was used in panning 
experiments (Tanha, J et ah, 2002). Panning against recombinant Caspase 3 protein was 
performed as described by Tanha et al. 2002, with the following changes. Phage elution in the 
second and third rounds additionally involved MgCl2/HCl treatment. To begin with, the bound 
phages in the microtiter wells were eluted with 200uL and neutralized with 100uL 1M Tris-HCl 
pH 7.4. Then, emptied wells were incubated with lOOuL of 4M MgCb at room temperature for 
15 min. The eluted phages were removed and the wells were incubated with lOOuL of lOOmM 
HC1 for five min at room temperature. The MgC^/HCl-eluted phages were pooled, neutralized 
with 1.5mL of 1M Tris-HCl pH 7.4, and combined with the triethylamine-eluted phages. One 
mL of these combined phages was used to infect E. coli for overnight phage amplification and 
the remaining lmL was stored at -80°C for future use. VHH clones were identified from the 
plates by plaque-PCR and sequencing as described (Tanha, J et ah, 2003). Following panning, 
phage clones from the plates were amplified in microtiter wells and screened for the ability to 
bind to Caspase 3 by ELISAs using a horse radish peroxidase/anti-M13 monoclonal antibody 
conjugate (GE Healthcare, Baie d'Urfe, QC, Canada) as the detection reagent. 
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3.3.1 Expression of VHHS in E. coli and Purification 
VHH genes were cloned from the phage vector into the expression vectors by established 
cloning techniques. Expression of VHHs in E. coli, followed by purification using immobilized 
metal affinity chromatography were performed as described (Tanha, J et ah, 2003). Protein 
concentrations were determined by A28o measurements using molar absorption coefficients 
calculated for each protein (Tanha, J et al, 2002). 
3.3.2 Formation of the VHH Fusion Constructs 
VHH genes were inserted in the Hind III/BamH I sites of pEGFP-Nl (VnH-green 
fluorescent protein (GFP) fusion) or pDsRedl-Nl (VHH-red fluorescent protein (RFP) fusion) 
(BD Biosciences, Mississauga, ON, Canada). The VHH recombinant vectors were propagated in 
E. coli and were purified using QIAprep® Spin Miniprep kit according to the manufacturer's 
instructions (QIAGEN, Mississauga, ON, Canada) by Dr.Tanha and associates in NRC-IBS 
Ottawa. 
3.4 Competitive Binding Assay 
3.4.1 Standardization of the Binding of cy5.5-labeled sdAb5.2 to Bax 
Maxisorp 96 well fluorescence plates (Nalge Nunc, Edmonton, AB) were coated with 
lOug/mL of purified Bax protein in PBS with protease inhibitors (lOuL/mL PMSF, luL/mL 
Leupep, luL/mL Pep A) and incubated overnight at 4°C. The following day the Bax solution 
was removed and the wells were blocked with 5mg/mL of BSA for 30min. The BSA was 
removed and the wells were coated with varying concentrations of cy5.5-labeled sdAb5.2 and a 
saturation curve for the binding between Bax and the labelled sdAb was produced. This 
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saturation curve was used for the determination of the Ka of the binding between Bax and cy5.5-
labeled sdAb, and subsequently the concentration of labelled sdAb used in the competitive 
binding assay. 
3.4.2 Screening of Compounds 1-34 for Competitive binding to Bax 
The Maxisorp 96 well plates were coated and incubated overnight with the 10|xg/mL Bax 
solution as described above. This was followed with removal of the supernatant and blocking 
with 5mg/mL of BSA for 30min. The BSA solution was removed and replaced with the K^ 
concentration of cy5.5-labelled sdAb5.2 (0.677uM) and the predetermined concentration of 
compounds (1-34) in reaction buffer (0.25M Sucrose, ImM MgCl2, lOmM HEPES, 4mg/mL 
PHPA, 20mM Succinate). This was incubated for 30min after which the supernatant was 
removed (unbound fraction) and the plate containing the bound fraction was washed twice with 
reaction buffer. The fluorescence of the supernatant was then read at 675nm excitation and 
694nm emission to determine the proportion of cy5.5-labelled sdAb5.2 that remained unbound, 
and the fluorescence of the plate (with fresh reaction buffer placed inside the wells) was read at 
the same excitation and emission to determine the proportion of cy5.5-labelled sdAb remained 
bound to the plate 
3.5 Blot Binding Assay 
In addition to the competitive binding assay, a blot binding assay was performed to 
confirm the results of the competitive binding assay. For this assay lug of purified recombinant 
Bax was run on an SDS gel and transferred to nitrocellulose. The nitrocellulose was stained 
with Ponseau for visualization of the Bax bands. These bands were excised and placed in the 
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bottom of the wells of a 96-well microtiter fluorescence plate. The wells containing the Bax 
bands were blocked with 5mg/mL of BSA solution for 30min, with the remainder of the assay 
performed as described above in "Competetive Binding Assay." 
3.6 Cell Culture 
3.6.1 Propagation of Cell Lines 
SHSY-5Y (Human Neuroblastoma) Cells and NT-2 (Human Tetracarcinoma) Cells were 
grown in Dulbelco's Modified Eagles Medium (DMEM) F-12 Ham supplemented with 10% 
(v/v) Fetal Bovine Solution (FBS), 2mM L-glutamine, and 20ug/mL gentamycin. The FBS 
involved in the maintenance of the NT-2 Cell Line was inactivated at 60°C prior to its addition to 
the DMEM. The cells were incubated at 37°C, 5% C02, and 95% humidity. 
3.6.2 Cell Line Subculturing 
Cells were thawed and grown in 25cm2 flasks sterile flasks and were subcultured by 
aspirating the media off and replacing with lmL 0.15% Trypsin EDTA and incubating at 37°C 
for 5min until the cells were capable of detaching with minimal force from the bottom of the 
flask. Following this, a predetermined amount of fresh media was added to the flasks and the 
cell suspension was aliquoted into 6-well or 10cm2 dishes as desired. 
3.6.3 Differentiation of SHSY-5Y Neuroblastoma Cells 
Plates that were to be used for culturing differentiated cells were first precoated with 
0.05mg/mL of collagen diluted in serum-free DMEM F-12 Ham and incubated for 30min in a 
sterile environment. The collagen solution was then removed, and the cells were added to the 
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plate in complete DMEM F-12 Ham media supplemented with lOuM retinoic acid for 5 days. 
After 5 days the media was removed and the cells were washed 3 times with serum-free DMEM 
F-12 Ham. The media was replaced with lOng/mL Brain Derived Neurotrophic Factor-
supplemented serum-free media and incubated for an additional 5 days. 
3.6.4 Transient Transfection of SHSY-5Y Cells 
FuGENE 6 Transfection Reagent was used to introduce the anti-Caspase 3 VHH 
constructs as well as the RFP constructs into SHSY-5Y cells that had been grown in 6-well 
plates using the ratio of 3uL of FuGENE reagent per lug of DNA as per manufacturer's 
protocol. The FuGENE was incubated for lOmin in lOOuL of serum-free media under sterile 
conditions in a laminar flow hood, following which, 1 ug of DNA was added to the solution and 
incubated for 45min. The total mixture was then added to each well of a 6-well plate and 
incubated at 37°C with 5% C02 and 95% humidity for 24h. 
3.7 Preparation of Post-nuclear Cytoplasmic Fraction 
In order to isolate the post-nuclear cytoplasmic fraction, cells were first grown to 70% 
confluency and removed from their 10cm plates by either mechanical dislodging or addition of 
lmL of 0.15% Trypsin EDTA. Cells that were mechanically removed were centrifuged at 500xg 
for 5min. The media as aspirated off and the cells (pellet) were washed twice in 1% PBS (pH 
7.4). After this, the pellet was resuspended in Hypotonic Buffer (lOmM Tris HC1 pH 7.2, 5mM 
KC1, ImM MgCl2, ImM EGTA, 1% Triton X-100) and incubated on ice for 5min. The cell 
suspension was then mechanically homogenized and centrifuged for 5min at 800xg at 4°C, 
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following which the supernatant was removed and kept and the pellet was discarded as it 
consisted of the nuclear pellet. 
3.8 Isolation of Mitochondria and Post-mitochondrial Cytosolic Fraction 
The post-nuclear supernatant that was isolated as described above was centrifuged again 
13,000 x g at 4°C for lOmin with once difference being the hypotonic buffer that was used in its 
initial isolation consisted of ImM EDTA, 5mM Tris HC1 pH 7.2, 210mM Mannitol, and 70mM 
Sucrose. The pellet obtained consisted of the mitochondrial fraction and the supernatant 
consisted of the post-mitochondrial cytosolic fraction. The crude mitochondrial pellet was 
resuspended in isotonic buffer (250mM Sucrose, ImM MgCl2, lOmM HEPES, 20mM Succinate) 
and kept on ice and used within 2h for experimentation. 
3.9 Monitoring Caspase 3 Activity: Measurement of the Effect the VRHS have on 
Caspase 3 Activity 
A fluorescence assay was used to evaluate the activity of active Caspase 3 in the presence 
or absence of the different VHHS. DEVD-AFC was used as the fluorescent substrate in this assay. 
This substrate, in the presence of reaction buffer (0.1M HEPES, 2mM DTT, 0.1% CHAPS, 1% 
sucrose, pH 7.4) and active Caspase 3, was incubated at 37°C for 60min and fluorescence was 
measured at 400nm excitation and 505nm emission using the SpectraMax Gemini XS (Molecular 
Devices, Sunnyvale, CA). Caspase 3 activity was measured as relative to the level of 
fluorescence. For inhibition assays, the VHHs were incubated with the active Caspase 3 for 
30min at 37°C prior to the addition of the DEVD-AFC in the reaction buffer. Following further 
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incubation for 60min, in a 96 well microliter plate, fluorescence was measured as described 
above. 
3.10Measurement of ROS Production from Isolated Mitochondria 
The effect each of the compounds has on the activity of Bax was estimated through 
incubation of Bax with isolated mitochondria in absence and in presence of the compound and 
subsequent measurement of the H2O2 (ROS) generation in each case. The amount of H2O2 
generated was determined using a fluorometric assay based on a previously published protocol using 
para-hydroxyphenylacetate (PHPA) as the fluorescent reagent (Li, N et al., 2003). Horse-Radish 
Peroxidase (HRP) couples the oxidation of PHPA to the stoichiometric reduction of H2O2, allowing 
for a direct correlation. The isolated mitochondria were resuspended in reaction buffer (lOmM 
HEPES (pH 7.4), 250mM Sucrose, ImM MgCl2, 20mM Succinate and 4mg/mL PHPA) and kept 
on ice while the protein estimation was performed on the suspensions. 
There were four types of reactions performed in each experiment. The first group included 
three control reactions for the reaction buffer alone, for mitochondria suspended in the reaction 
buffer, and for mitochondria incubated with Bax. The other reaction types were analogous to the 
third control group, but with the addition of 20 uM of the compound tested. All reactions contained 
4mg/mL PHPA, 10 |ig/mL of Bax, 100 ug/mL of mitochondria, and 4U of HRP (added last), and the 
final volume in each well was kept constant, at 200uL. Each reaction was done in triplicate and read 
at 320nm excitation and 400nm emission using the Spectra Max Gemini XS immediately after the 30 
min incubation at 37°C. 
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3.11 Western Blot 
All the western blots that were conducted used the following protocol with variations in 
the primary and secondary antibody as needed (monoclonal anti-Bax, polyclonal anti-VDAC, 
monoclonal anti-caspase 3, and polyclonal anti-actin,). Protein samples were resolved using 
either 12% or 15% SDS-PAGE and loading between l|ag-50|ig of protein per well. The protein 
was transferred from the gel onto a nitrocellulose membrane which was subsequently blocked 
using a non-fat milk solution (5% milk in TBST) for lh on a shaker at room temperature. The 
membrane was then incubated with the required primary antibody at a dilution of either 1:1000 
or 1:2000 (dependent on the antibody chosen) in 2% non-fat milk solution, overnight at 4°C (12-
18h). After this incubation period, the membrane was washed with TBST for 15min, followed 
by three 5min washes and incubated with the secondary antibody (anti-mouse IgG (whole 
molecule) or anti-rabbit (whole molecule) peroxidase conjugate) at a dilution of 1:2000 in 2% 
milk solution and incubated at room temperature on a shaker for lh. The blots were then 
developed using a ChemiGlow West kit according to manufacturer's protocol and recorded using 
an Alpha Innotech Corporation Imaging System. 
3.12 Induction of Oxidative Stress 
3.12.1 Hydrogen peroxide Method 
Utilizing a stock H2O2 of 10M, a working stock solution of lOOmM H2O7 was made by 
diluting with ddHaO. The stock solution was refrigerated and stored out of light and checked 
periodically over its shelf life to ensure a lack of degradation. SHSY-5 Y, differentiated SHSY-
5Y, transiently transfected SHSY-5Y, or NT-2 cells were grown to 70% confluence and treated 
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with either 50uM or lOOuM H2O2 for lh at 37°C. Following this, the media was replaced with 
fresh, complete media and the cells were incubated for varying time periods and monitored for 
apoptotic features and protein expression. 
3.12.2 Hypoxia/Hypoglycemia Model 
SHSY-5 Y cells were grown to70% confluence and placed in an oxygen free chamber in a 
salt solution (1 lOmM NaCl, 5.4mM KC1, 0.8mM MgCl2, 1.8mM CaCl2, 15mM NaHC03 15mM 
HEPES, 50mM Glycine pH 8) instead of the usual complete DMEM F-12 Ham media for 12-24h 
at 37°C. After this treatment, cells were removed from the chamber and the salt solution was 
replaced with fresh complete medium and cells were analyzed 24h later. 
3.13 Monitoring Apoptosis 
3.13.1 Cellular Staining Techniques 
3.13.1.1 Nuclear Morphology: Hoechst 33342 Staining 
Cells that were placed under oxidative stress conditions were monitored for signs of 
apoptotic nuclei via Hoechst 33342 staining. The Hoechst stain was added to a cellular 
suspension to achieve a final concentration of 10uM and incubated for lOmin at room 
temperature in dark conditions. The cells were then examined using fluorescent microscopy and 
brightly stained, condensed nuclei were taken as apoptotic nuclei. The pictures were processed 
using Improvision OpenLab v3.1.2 and Adobe PhotoShop v8.0. 
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3.13.1.2 Monitoring Plasma Membrane Flipping: Annexin V Staining 
Annexin V conjugate was used to monitor the plasma membrane flipping that occurs in 
cells undergoing apoptosis. Cells were removed from their plates by either trypsinization or 
mechanical dislodging and washed twice with PBS. The cellular pellets were resuspended in 
Annexin V Binding Buffer (lOmM HEPES, lOmM NaOH pH 7.5, 140mM NaCl, 2.5mM CaCl2, 
50mM Sucrose) with the Annexin V Binding Dye was added to the suspension at a 1:1000 
dilution. This suspension was incubated for 15min at room temperature in the dark and lOuL 
samples were pipetted onto slides and examined using fluorescent microscopy as described 
above. 
3.13.1.3 Monitoring Mitochondrial Membrane Potential: JC-1 Staining 
JC-1 staining was used to monitor the mitochondrial membrane potential which becomes 
disrupted in cells undergoing apoptosis. JC-1 dye was added to cellular suspensions to a final 
concentration of lOuM and incubated for 45min at 37°C in the dark. The cells were examined 
using fluorescent microscopy as described above. 
3.13.2 Monitoring Intracellular ROS and Protease activity 
3.13.2.1 Mitochondrial ROS 
Cells that were treated under oxidative stress conditions were harvested and their 
mitochondria were isolated as described above. These mitochondria were analyzed for their 
levels of ROS using an Amplex Red assay. Isolated mitochondrial pellets were resuspended in 
the Amplex Red reaction buffer (2.5mM malate, lOmM succinate), Amplex reagent was added to 
a final concentration of 50uM, and HRP was added in the ratio of 6U/200uE. The mixture was 
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incubated at room temperature for 30min prior to reading the fluorescence at 560nm excitation 
and 590nm emission. 
3.13.2.2 Caspase 3 Activity 
Cells that had been subjected to oxidative stress treatment were harvested and their post-
nuclear cytoplasm was isolated as described above. The Caspase 3 activity was monitored 
fluorometrically using a DEVD-AFC. This substrate, in the presence of reaction buffer (0.1M 
HEPES, 2mM DTT, 0.1% CHAPS, 1% sucrose, pH 7.4) and lOOug of post-nuclear cytoplasm 
sample, was incubated at 37°C for 60min and fluorescence was measured at 400nm excitation 
and 505nm emission using the SpectraMax Gemini. Caspase 3 activity was expressed as relative 
fluorescence per lOO îg of protein. 
3.13.2.3 Immunoprecipitation 
Immunoprecipitation was performed to examine the effect of the compounds on the 
interaction between Bax and VDAC. Mitochondrial fractions were isolated as described above 
for cells that were completely untreated, placed under oxidative stress and either treated 
with/without compound. A solution of luT anti-VDAC polyclonal antibody with lOuL protein 
G-Sepharose beads was made in 300uL RIPA buffer (20mM Tris-OH, 150mM NaCl, lOmM 
KC1 and 1% triton X-100) and incubated for lh at 4°C. Approximately 60u.g of mitochondrial 
protein from each cell type was added to the pre-incubated anti-VDAC solution described above, 
and both samples were incubated overnight (~18h) at 4°C on a shaker. The immunoprecipitates 
were collected by centrifugation at 500 x g for 2 min at 4°C followed by washing the pellet three 
times with RIPA buffer. After the final wash the pellet was resuspended in 30uL of RIPA buffer 
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and mixed with 1 OuL of SDS loading buffer and the samples were analyzed using SDS-PAGE 
and Western Blot as previously described. 
Chapter 4: Results' 
Parti 
4.1 Purification of Recombinant Caspase 3 for Identification of anti-Caspase 3 sdAbs 
(VHHS) and Caspase 3 Activity Assay 
Recombinant Caspase 3 was expressed in E. coli, in fusion with a His6 tag and was 
subsequently purified by immobilized metal affinity chromatography. Purified protein was 
eluted by an imidazole buffer was confirmed to be Caspase 3 by Coomassie staining and 
Western blotting. It was shown that purified Caspase 3 was present in both active (15kDa) and 
inactive forms (35kDa) (figure 4.1). The recombinant Caspase 3 was subsequently used for 
panning experiments against a naive llama VHH phage display library (Tanha et al, 2002) and 
for Caspase 3 activity assays. 
4.2 Identification, Binding, and In Vitro Functional Analysis of anti-Caspase 3 sd Abs 
(VHHs) 
Pro/anti-apoptotic proteins are prime targets for selective modulation of apoptosis in 
treating neurodegeneration and cancer. Caspase 3 is a known universal executioner protein of 
apoptotic pathway and, thus, a key protein to modulate. In order to obtain apoptosis-modulating 
antibodies, we panned a nai've llama VHH phage display library (Tanha, et al., 2002) against 
recombinant Caspase 3. Screening of 22 colonies gave two different VHH sequences, 
VhhCasp31 and VhhCasp32, occurring at frequencies of 19 and 3, respectively (figure 4.2A). 
The VHHs had the marker amino acids described previously (Harmsen, et al., 2000). Both VHHs 
bound strongly to Caspase 3 but not to a control protein, bovine serum albumin in phage ELISAs 
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(figure 4.2B). VHHS were expressed in fusion with C-terminal c-Myc-His5 tag in E. coli and 
purified to homogeneity for subsequent functional studies. 
Next, we performed Caspase 3 activity assays to determine if VhhCasp31 and 
VhhCasp32 alter the activity of Caspase 3. A tetra-peptide substrate (DEVD) conjugated to AFC 
was used in this assay. In the presence of active Caspase 3 the substrate is cleaved, releasing the 
fluorescent AFC which then gives a measure of activity of Caspase 3. Caspase 3 was pre-
incubated with VHHS prior to the addition of the reaction buffer and DEVD-AFC substrate and 
the activity of Caspase 3 was monitored for decreases or increases in comparison to the reaction 
without any VHH or with an irrelevant VHH. AS can be seen in figure 4.2C in the presence of an 
equimolar concentration of VhhCasp31 (4.7uM), the activity of Caspase 3 (4.7uM) decreases to 
61% compared to a non-treated control (100%). Conversely, VhhCasp32 treatment at the same 
concentration resulted in an increase in Caspase 3 activity of 22.5%. The effect of the VHHs on 
Caspase 3 was also found to be concentration dependent: at VhhCasp31 concentrations three 
times that of Caspase 3 (14.1uM); Caspase 3 activity was decreased to as low as 14.5% of 
control. At the same concentration, VhhCasp32 treatment led to a 38% increase in Caspase 3 
activity. When treated with an irrelevant VHH, Vhh5.2, under both concentration conditions, 
Caspase 3 demonstrated negligible changes in activity (figure 4.2C), ruling out the possibility 
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Figure 4.1: Coomassie gel and Western blot of purified recombinant Caspase 3 
Coomassie staining and Western blot show bands reacting with anti-Caspase 3 antibodies of the expected size of 
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Figure 4.2A: Amino acid sequence of VhhCasp31 and VhhCasp32 
Complementarity determining regions 1 (CDR1), CDR2 and CDR3 are underlined and appear sequentially. Dashes 
are included for sequence alignment. 
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Figure 4.2B: Binding analysis of VhhCasp31 and VhhCasp32 
The graph shows the binding, by ELISA, of VHH-displayed phages VhhCasp31 and VhhCasp32 to immobilized 
Caspase 3 (columns 1 & 2). The VHH-phages did not bind to non-specific bovine serum albumin (columns 3 &4). 
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Figure 4.2C: Modulating effect of VhhCasp31 and VhhCasp32 on Caspase 3 activity 
4.7uM of active recombinant Caspase 3 was treated with an equal (purple) or 3-fold (green) concentration of 
VhhCasp31, VhhCasp32 or Vhh5.2 VHH control. The activity of the Caspase 3 was measured in terms of 
fluorescence release into solution relative to the fluorescence release observed with Caspase 3 alone as described in 
Materials and Methods. Experiments were performed in triplicates and standard errors were calculated using 
Microsoft Excel software. 
I Q U 
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4.3 Effects of Transiently-expressed VhhCasp31 and VhhCasp32 Intrabodies on 
Oxidative Stress induced Apoptosis in SHSY-5Y cells 
Although the results described above indicated that VHHS were capable of binding as 
well as modulating the in vitro activity of Caspase 3, it remained to be determined if they would 
affect Caspase 3 when expressed inside mammalian cells, and, thus, modulate apoptosis. We 
therefore set out to determine the effects of the VHHS expressed intracellularly as intrabodies on 
apoptosis. In order to accomplish this, vectors for expression of VhhCasp31 and VhhCasp32 
VHHS as intrabodies in SHSY-5Y mammalian cells were constructed (Gueorguieva, et al, 2006). 
Following transfection with VhhCasp31- and VhhCasp32-containing expression vectors, the 
cells were challenged with 50uM H2O2 and observed for physiological changes associated with 
apoptotic cell death by cellular staining with Hoecsht and Alexa Fluor 594-Annexin V. Hoechst 
dye intercalates with the DNA and thus, highly condensed nuclei like those associated with 
apoptosis, will fluoresce brightly when viewed under a fluorescent microscope. The Annexin V 
conjugate binds to phosphatidylserine, a marker for early apoptosis. Thus, cells that fluoresce 
red will be indicative of apoptosis. The VHHS were expressed as a fusion protein conjugated to 
green fluorescent protein, so that a successful VHH expression can be "visualized" as green 
fluorescence. It can be seen in figure 4.3A that non-transfected SHSY-5Y cells that were not 
challenged with H2O2 did not show apoptotic nuclei upon Hoechst staining. Also, no positive 
Annexin V staining indicated healthy, non-apoptotic cells. 
Signs of apoptosis can be seen in non-transfected cells challenged with 50uM H2O2, 
indicated by brightly stained, condensed nuclei by Hoechst staining and positive red Annexin V 
staining (figure 4.3B). SHSY-5Y cells were also transfected with a vector expressing green 
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fluorescent protein (GFP) alone. These cells were also challenged with 50uM H2O2 and upon 
staining with Annexin V (red) it can be seen that the GFP does not offer any protection from 
apoptosis (figure 4.3C) . In contrast, the apoptosis modulating effects of VhhCasp31 and 
VhhCasp32 can be seen in cells expressing these VHH intrabodies. Cells transfected with 
VhhCasp31 and challenged with 50uM H2O2 do not display morphology and staining indicative 
of apoptosis (figure 4.3E), just like the unchallenged VhhCasp31-transfected cells (figure 4.3D). 
Lastly, it can be noted in figure 4.3F and figure 4.3G that cells transfected with VhhCasp32 
display signs of apoptosis even without H2O2 treatment. These results indicate that VhhCasp31 
is an antagonist and VhhCasp32 is an agonist of apoptosis. 
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Figure 4.3: Cellular and nuclear morphology of VhhCasp31- and VhhCasp32-transfected SHSY-5Y cells. 
Control (nontransfected) SHSY-5Y cells were passaged at the same point as the transfected SHSY-5Y cells and 
stained with cell permeable Hoechst dye to visualize healthy viable cells. Annexin V Fluor conjugate 594 was also 
used to visualize any apoptotic cells as described in Materials and Methods. The concentration of H202 used was 
50uM. As seen in panels D-E, column "GFP", all the VHH-tranfected cells are green indicating a successful 
expression of VHH-GFP fusion proteins. All fluorescent pictures were taken using an inverted stage fluorescence 
microscope (Magnification: 400x). 
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Part 2 
4.4 Purification of Recombinant Bax for Binding Assays and Mitochondrial ROS 
Generation 
In order to carry out the competitive and blot binding assays, as well as mitochondrial 
ROS generation, pro-apoptotic protein Bax was isolated and purified from a culture of E.coli 
cells transformed with the box gene harbouring an N-terminal polyhistidine-tag through affinity 
chromatography using a Ni2+ chelating column (as described in the methods of Chapter 3). The 
presence of the N-terminal polyhistidine-tagged protein allowed for the use of a metal affinity 
resin as a method for purifying recombinant Bax. The resin in the HiTrap column utilizes a 
tetradentate metal chelator to bind the Ni2+ ions by occupying four of the six coordination sites of 
he octahedral binding structure of the metal ion. The remaining two sites are left available for 
interactions with imidazole ring of the His tails on recombinant Bax. Using a low concentration 
of imidazole, non-specific proteins were eluted from the column, as imidazole alone has the 
potential to interact with Ni2+. This was followed by elution of the recombinant Bax using a high 
concentration of imidazole. 
Following purification, the Bax fraction obtained was analyzed using SDS-PAGE and 
Western blot to ensure purity. Bax is identified as the 40kDa band (figure 4.4) by Western blot, 
indicating that it was isolated in the homodimer form due to the presence of the non-ionic 
detergent Triton X-100 used during the purification process (Hsu, Y-T et al, 1997). In this case, 
20ug of protein was loaded into the SDS gel, which was subsequently transferred onto a 
nitrocellulose membrane. The membrane was then probed with monoclonal anti-Bax IgG 
(primary antibody) that has the recognition site N-terminus of Bax, common to isoforms a, 5, 
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and p in a 1:1000 dilution in 2% non-fat milk solution. The blot was further probed with a 
monoclonal anti-mouse HRP conjugate (secondary antibody) using a 1:2000 dilution and 
developed using ChemiGlow West kit, showing a positive band at 40kDa for Bax. The 
experiment was subsequently repeated for each individual purification with similar results. 
4.5 Standardization of Binding of cy5.5-labeled sdAb5.2 to Bax 
Prior to performing any analysis on the ability of the members of the pharmacaphore 
library to bind competitively to purified Bax in the presence of cy5.5-labeled sdAb5.2, a 
saturation curve characterizing the concentration-dependent binding of cy5.5-labeled sdAb5.2 to 
Bax was required (figure 4.5). SdAb5.2 was selected for fluorescent labelling with cy5.5 on its 
Lys residues, as it possessed the greatest ability to inhibit the function of Bax under oxidative 
stress conditions (Gueorguieva, et al., 2006). Varying concentrations of cy5.5-labeled sdAb5.2 
were added to wells that were precoated overnight with purified homodimer Bax (as described in 
Chapter 3) and incubated for 30min. Following this, it was determined relative to fluorescence 
how much was bound to Bax, up until its saturation point (at approximately lOuM). For the 
purpose of a competitive binding assay involving small molecular weight compounds, it was 
necessary to determine the concentration of cy5.5-labeled sdAb5.2 where half of the binding 














Figure 4.4: Western blot of recombinant purified Bax 
is were anaylyzed for purity through Western Blot using a monoclonal anti-Bax primary 
modimer (40kDa) was detected after incubation with secondary anti-body (anti-mouse IgG 
.yugate) and developed using a ChemiGlow West kit. 
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Concentration-Dependent Binding of cy5.5-
labeled sdAb 5.2 to Bax 
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Figure 4.5: Binding curve of cy5.5-labelled sAb5.2 to Bax 
Varying concentrations of labelled sdAb5.2 were added to immobilized Bax up to a saturation concentration of 
10|aM and fluorescence was measured using the SpectraMax Gemini XS fluorescence plate reader. The Kd of 
labelled sdAb5.2 was determined to be 0.67uM and was the concentration used for subsequent competitive binding 
assays. 
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This corresponds to the Kd of cy5.5-labeled sdAb5.2. If Bax were to be fully saturated with the 
labelled antibody, this would not afford the pharmacaphore the chance to properly compete for 
binding sites on Bax. The Kd was determined to be 0.67^M and this was the concentration of 
labelled antibody subsequently used in all competitive binding experiments. 
4.6 Ability of Pharmacaphore Library Compounds (1-34) to Bind to Bax in the 
Presence of cy5.5-labeled SdAb: Competitive Binding Assay 
Once the Kd of cy5.5-labeled sdAb5.2 was determined, the 34 small molecule members 
of the pharmacaphore library were tested for their ability to compete with the labelled antibody 
for binding sites on Bax. Immobilized Bax was incubated with 0.67uM of the labelled sdAb 
along with 10(iM, 20uM, and 40^M of the pre-chosen compound. The results for 20uM 
concentration of compound are shown below, as this was the comparable concentration used for 
the ROS studies, which were performed in tandem with the binding studies. Following 30min of 
incubation of the labelled sdAb and the chosen compound with Bax, the supernatant was 
removed. This supernatant contained any unbound compound as well as any unbound labelled 
sdAb. This supernatant was compared with two control supernatants; one which was from a well 
with 0.67uM of labelled sdAb, but no immobilized Bax, and the other which contained 
immobilized Bax as well as labelled antibody. The wells which did not have any immobilized 
Bax should theoretically have no labelled sdAb binding, and thus have the maximum present in 
the supernatant, whereas wells with immobilized Bax and labelled sdAb, without any compound 
present should have the maximum amount of labelled antibody bound. The relative fluorescence 
of the supernatant from the wells lacking immobilized Bax, but incubated with the labelled sdAb 
was thus taken as 100% relative fluorescence. In fact, the wells containing labelled sdAb, but 
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without immobilized Bax displayed on average 4.249%-15.36% of labelled sdAb that remained 
bound to the plate. In the wells that contained immobilized Bax incubated with labelled sdAb 
alone, the percent relative fluorescence readings for the supernatant had values on average 
between 58.12-66.88%, and the percent relative fluorescence of the bound was between 30.61-
50.2%. If a particular compound was capable of competing with the labelled sdAb for binding 
spots, then the displaced labelled sdAb should be present in the supernatant, thus increasing the 
fluorescence of the supernatant, giving a percent relative fluorescence value above 66.88%. The 
plate, that possessed the bound fractions, was washed to remove any loosely bound labelled 
antibody and compound. This plate was read to determine the amount of labelled sdAb that 
remained bound after incubation with the designated compound. 
4.6.1 Compounds that did not display competitive binding specifically for Bax 
Out of the 34 compounds that were screened, 25 did not show any ability to 
competitively bind to Bax in the presence of the labelled sdAb. This means that when compared 
to wells that contained only immobilized Bax and labelled sdAb, there should be a similar 
binding profile. This is what was seen for compounds 1-6 (figure 4.6.1 A), compounds 7-12 
(figure 4.6.1B), compounds 13-15, 18, and 20 (figure 4.6.1C), and compounds 21, 27-29, 32, and 
34 (figure 4.6.ID). There was no change in the amount of labelled sdAb bound to immobilized 
Bax (it remains constant between 30.61-46.75%), meaning the compound did not compete for 
binding sites, and there was no increase in fluorescence in the supernatant (it remained between 
50.89-68.71%). 
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Effect of Compounds 1-6 on Binding of cy5.5-
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Figure 4.6.1A: Compounds 1-6 do not compete with cy5.5-labeled sdAb5.2 for Bax binding sites 
Following 30min of incubation with labeled sdAb5.2 and immobilized Bax, compounds 1-6 were not able to 
compete for binding sites on Bax. There was no change in unbound portion of labeled sdAb, as none was dislodged 
•• ̂ m Bax binding sites. The amount bound and unbound was measured relative to fluorescence, which was 
nred using the SpectraMax Gemini XS fluorescence plate reader. 
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Effect of Compounds 7-12 on Binding of cy5.5-
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Figure 4.6.1B: Compounds 7-12 do not compete with cy5.5-labeled sdAb5.2 for Bax binding sites 
Following 30min of incubation with labeled sdAb5.2 and immobilized Bax, compounds 7-12 were not able to 
nnete for binding sites on Bax. There was no change in unbound portion of labeled sdAb, as none was dislodged 
•;: Bax binding sites. The amount bound and unbound was measured relative to fluorescence, which was 
measured using the SpectraMax Gemini XS fluorescence plate reader. 
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Effect of Compounds 13-15 and 18-20 on Binding 
of cy5.5-labeled sdAb5.2 to Bax 
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Figure 4.6.1C: Compounds 13-15, and 18-20 do not compete with cy5.5-labeled sdAb5.2 for Bax binding sites 
Following 30min of incubation with labeled sdAb5.2 and immobilized Bax, compounds 13-15 and 18-20 were not 
able to compete for binding sites on Bax. There was no change in unbound portion of labeled sdAb, as none was 
dislodged from Bax binding sites. The amount bound and unbound was measured relative to fluorescence, which 
was measured using the SpectraMax Gemini XS fluorescence plate reader. 
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Effect of Compounds 21, 27-29, 32, and 34 on 
Binding of cy-5.5-labeled sdAb5.2 to Bax 
• Unbound 
• Bound 
sdAb sdAb cmpd cmpd cmpd cmpd cmpd cmpd 
w/o w/Bax 21 27 28 29 32 34 
Bax 
Figure 4.6.1D: Compounds 21, 27-29,32, and 34 do not compete with cy5.5-labeled sdAb5.2 for Bax binding 
sites 
Following 30min of incubation with labeled sdAb5.2 and immobilized Bax, compounds 21, 27-29, 32, and 34 were 
not able to compete for binding sites on Bax. There was no change in unbound portion of labeled sdAb, as none was 
dislodged from Bax binding sites. The amount bound and unbound was measured relative to fluorescence, which 
was measured using the SpectraMax Gemini XS fluorescence plate reader. 
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4.6.2 Compounds Displaying Competitive Binding Specifically for Bax 
Out of the 34 compounds, there were 9 that appeared to competitively bind to 
immobilized Bax in the presence of the cy5.5-labelled sdAb5.2. When compared to the control 
well without immobilized Bax, containing labelled sdAb alone, there was a similar binding 
profile. This is what was seen for compounds 13-15 and 22-24 (figure 4.6.2A), and 25, 30, 31, 
and 33 (figure 4.6.2B). There was a difference in the amount of labelled sdAb bound to 
immobilized Bax (it decreased to between 8.214-38%), meaning the compound did compete for 
binding sites, and there was an increase in fluorescence in the supernatant (between 77.25-
94.4%). 
4.7 In Vitro Measurement of Mitochondrial ROS Due to Bax: Effect of Pharmacaphore 
Compounds on ROS Levels 
The 34 compounds were initially tested to understand if binding to Bax would translate 
into inhibition of its function. Since there is no direct measure of Bax activity on mitochondria, 
we chose to measure the ROS production by mitochondria incubated with active Bax 
homodimer. Previous work in our laboratory has shown that in presence of isolated 
mitochondria, Bax is able to permealize the MOM and subsequently lead to increase in ROS 
production (Naderi, J et al, 2006). ROS was detected fluorimetrically via measurement of the 
oxidation of PHPA coupled to the reduction of H2O2 by horseradish peroxidase (HRP). Thus, if 
by binding to Bax the 34 compounds were able to individually block the detrimental effect of 
Bax on the mitochondria, we would expect lowered fluorescence in samples containing isolated 
mitochondria, Bax, and compound in comparison to the positive control of mitochondria and 
Bax alone. 
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The data collected for this section represents a compilation of three to five independent 
experiments. In each individual experiment, the fluorescence detection for the negative control 
(mitochondrial alone) was subtracted from each subsequent fraction (e.g. the fractions containing 
mitochondria, Bax, and compounds). Additionally, the positive control fraction (mitochondria 
with Bax only) was taken as 100% fluorescence (or 100% ROS) and the fluorescence of all test 
samples (mitochondria, Bax, and compounds) were calculated relative to this control. The 
results were grouped together as either having no effect on Bax-induced ROS, an intermediate 
effect on Bax-induced ROS, or having a lowering effect on Bax-induced ROS. 
4.7.1 Compounds Displaying no Effect on Bax-induced Mitochondrial ROS at 20uM 
Concentration 
Considering the 34 compounds, there were 4 compounds (compounds 9, 27, 32, and 34) 
that did not affect the level of Bax-induced mitochondrial ROS (figure 4.7.1). When compared 
to the positive control (Bax incubated with isolated mitochondria), which was designated as 
100% relative fluorescence, the levels of percent relative fluorescence were all close to 100% 
(between 85-105% ± standard deviation). Interestingly, in the previous competitive binding 
studies, these compounds did not show any ability to competitively bind to Bax in the presence 
ofcy5.5-labelledsdAb5.2. 
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Effect of Compounds 16,17, 22-24 on Binding 
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Figure 4.6.2A: Compounds 16,17, and 22-24 compete with cy5.5-labeled sdAb5.2 for Bax binding sites 
Following 30min of incubation with labeled sdAb5.2 and immobilized Bax, compounds 16, 17, and 22-24 were able 
to compete with the labeled sdAb for binding sites. This was reflected in the significant increase of fluorescence 
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Effect of Compounds 25, 30, 31 , and 33 on 
Binding of cy5.5-labeled sdAb5.2 to Bax 
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Figure 4.6.2B: Compounds 25,30,31, and 33 compete with cy5.5-labeled sdAb5.2 for Bax binding sites 
Following 30min of incubation with labeled sdAb5.2 and immobilized Bax, compounds 25, 30, 31, and 33 were able 
to compete with the labeled sdAb for binding sites. This was reflected in the significant increase of fluorescence 
found in the unbound supernatant fractions, and the decrease in fluorescence of the bound fractions. 
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4.7.2 Compounds that had an Intermediate Effect on Lowering the Level of Bax-Induced 
Mitochondrial ROS 
There were 17 compounds that had an intermediate effect on lowering the level of Bax -
induced mitochondrial ROS which can be seen in figures 4.7.2A and 4.7.2B. The level of ROS 
was reduced to values between 40 and 80% relative fluorescence when compared to the positive 
control in this group of compounds. Out of these 17 compounds, only compounds 24 and 31 
also displayed an ability to competitively bind to Bax in the presence of the labeled sdAb (see 
figure 4.6.2A). 
4.7.3 Compound that increased the level of Bax-Induced Mitochondrial ROS 
There was only one compound that increased the level of Bax-induced mitochondrial 
ROS, thus causing oxidative stress. Compound 25 increased the level of mitochondrial ROS by 
30% when compared to the 100% relative fluorescence of the positive control (Bax incubated 
with mitochondria alone) (figure 4.7.3). Furthermore, compound 25 displayed an ability to 
^mpetitively bind to Bax in the presence of the labeled sdAb (see figure 4.6.2B). 
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Mitochondrial ROS Levels After Incubation with 
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Figure 4.7.1: Compounds 9,27,32, and 34 have no effect on the level of Bax-induced mitochondrial ROS 
Mitochondria (lOOfig/mL), isolated from SHSY-5Y, cells were incubated with 10ng/mL of Bax either in the 
presence or absence of compounds 9, 27, 32, or 34 in a reaction buffer and ROS generation was measured as 
described in Methods. ROS generated by Bax alone was taken as 100%. The compounds did not affect ROS 
generation and retained a percent relative fluorescence close to 100%. Fluorescence was monitored after 30min and 
red using the SpectraMax Gemini fluorescence plate reader and the standard error shown as error bars was 
calculated using Microsoft Excel program and the data obtained from six separate experiments. . 
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Mitochondrial ROS Levels After Incubation with 
Compounds 1-7, and 10 (Expressed as % of Normal 
Activity) 
Normal Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 
Activity 10 
Figure 4.7.2A: Compounds 1-7 and 10 have an intermediate effect on lowering Bax-induced mitochondrial 
ROS 
Mitochondria (lOOug/mL), isolated from SHSY-5Y, cells were incubated with 10ng/mL of Bax either in the 
presence or absence of compounds 1-7 or 10 in a reaction buffer and ROS generation was measured as described in 
Methods. ROS generated by Bax alone was taken as 100%. The compounds had an intermediate effect on ROS 
generation; lowering levels by approximately 40-60% relative fluorescence. Fluorescence was monitored after 
30min and read using the SpectraMax Gemini fluorescence plate reader and the standard error shown as error bars 
was calculated using Microsoft Excel program and the data obtained from six separate experiments. . 






















Mitochondrial ROS Levels After Incubation with 
Compounds 23-26, 28-31, 33 (Expressed as % of Normal 
Activity) 
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Figure 4.7.2B: Compounds 23,24, 26, and 29-33 have an intermediate effect on lowering Bax-induced 
mitochondrial ROS 
Mitochondria (100u,g/mL), isolated from SHSY-5Y, cells were incubated with 10u.g/mL of Bax either in the 
^-esence or absence of compounds 23-26, 28-31, or 33 in a reaction buffer and ROS generation was measured as 
scribed in Methods. ROS generated by Bax alone was taken as 100%. The compounds had an intermediate effect 
on ROS generation; lowering levels by approximately 30-60% relative fluorescence. Fluorescence was monitored 
after 30min and read using the SpectraMax Gemini fluorescence plate reader and the standard error shown as error 
bars was calculated using Microsoft Excel program and the data obtained from six separate experiments. 
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4.7.4 Compounds that Significantly Lowered the Level of Bax-Induced Mitochondrial 
ROS 
There were 5 compounds that demonstrated the ability to significantly lower Bax-induced 
mitochondrial ROS, thus offering some protection against oxidative stress. Compounds 8, 17, 
18, 20, and 22 lowered mitochondrial ROS to 20-30% when compared to the positive control 
(100% relative fluorescence) as seen in figure 4.7.4. Out of these 5 compounds, compound 17 
and 22 also displayed an ability to competitively bind to Bax in the presence of the labeled sdAb 
(see figure 4.6.2A). However, the competitive binding of compound 17 was shown to be very 
weak as seen in figure 4.6.2A, whereas the competitive binding of compound 22 was stronger, 
thus making compound 22 a desirable compound to study further in terms of its protective 
abilities. Compounds 8, 18, and 20 did not previously show any ability to competitively bind to 
Bax; however they could be protecting the mitochondria in another manner. 
4.7.5 Effect of Varying Concentrations of Compound 22 on Mitochondrial ROS Levels 
Since we observed that compound 22 was not only capable of competitive binding to Bax 
in the presence of the labelled sdAb, but was also able to significantly lower the levels of Bax-
induced ROS at 20uM concentration, it was important to observe the effect of compound 22 at 
higher concentrations and in comparison to the known anti-oxidant Coenzyme Qio (CoQio). 
CoQio, at a concentration of 230uM, was shown to lower the relative ROS levels to 40%. 
Previous studies have shown that water-soluble CoQio has the ability to lower Bax-induced ROS, 
making it a valuable positive control (Naderi et ai, 2006). Furthermore, when the concentration 
of compound 22 was elevated to 30 and 40uM, a reduction in relative ROS to 20% and 10% 
respectively was noted (figure 4.7.5). The next step would be to observe if this trend could be 
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translated to neuronal precursor (SHSY-5Y) cells. This in vivo model would allow us to monitor 
the effects of concentration of compound 22 on cell viability and toxicity, in addition to its 
protective abilities in oxidative stress conditions. 
4.8 Blot Binding Assay: Confirmation of Binding of Compound 22 to Bax in the 
Presence of cy5.5-labeled sdAb5.2 
Prior to commencement of the in vivo studies involving compound 22, confirmation via 
an alternative competitive binding assay was required. For this, a blot binding assay was 
utilized. In this assay, purified recombinant Bax was run on an SDS gel and transferred to 
nitrocellulose paper. This ensured that Bax was immobilized prior to incubation with the 
labelled sdAb and compound and was not lifting off, making it present in the supernatant. It can 
be seen in figure 4.8 that compound 22 does indeed competitively bind to Bax in the presence of 
labelled sdAb. This was compared with a compound that was found to be non-specific for Bax 
in the previous competitive binding assay (compound 9). In this blot binding assay, the 
fluorescence given by the bound fraction in the wells containing immobilized Bax with labelled 
sdAb alone was taken as 100% relative fluorescence, and all other fluorescent values were taken 
relative to this. It can be observed in figure 4.8 that when the immobilized Bax and labelled 
sdAb were incubated with compound 22, the relative fluorescence value of the bound fraction 
decreased to 45.58% ±12.39% and the unbound or supernatant fraction increased to 78.759% 
±15.40%, indicating that there was competition for binding sites on Bax. In comparison, when 
incubated with the nonspecific compound 9, the relative fluorescence value of the bound fraction 
remained at nearly 100% with 
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Figure 4.7.3: Compound 25 increases the level of Bax-induced mitochondrial ROS 
Mitochondria (100(xg/mL), isolated from SHSY-5Y, cells were incubated with lOjig/mL of Bax either in the 
presence or absence of compound 25 in a reaction buffer and ROS generation was measured as described in 
Methods. ROS generated by Bax alone was taken as 100%. Compound 25 increased ROS generation by 
inproximately 30% relative to the control. Fluorescence was monitored after 30min and read using the SpectraMax 
vicmini fluorescence plate reader and the standard error shown as error bars was calculated using Microsoft Excel 











Mitochondrial ROS Levels After Incubation with Compounds 8, 
17,18, 20 & 22 (Expressed as % of Normal Activity) 
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Figure 4.7.4: Compound 8,17,18,20, and 22 significantly lower the level of Bax-induced mitochondrial ROS 
Mitochondria (100u.g/mL), isolated from SHSY-5Y, cells were incubated with lOug/mL of Bax either in the 
presence or absence of compounds 8,17,18,20, or 22 in a reaction buffer and ROS generation was measured as 
described in Methods. ROS generated by Bax alone was taken as 100%. The compounds had a significant effect on 
lowering ROS generation; lowering levels by approximately 70-80% relative to the control. Fluorescence was 
monitored after 30min and read using the SpectraMax Gemini fluorescence plate reader and the standard error 
shown as error bars was calculated using Microsoft Excel program and the data obtained from six separate 
experiments. 
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Mitochondrial Dysfunction (Induction by H202) 























Bax + CoQIO 230p.M cmpd 22 30p.M cmpd 22 40p.M 
mitochondria 
Figure 4.7.5: Effect of varying concentration of compound 22 on levels of Bax-induced mitochondrial ROS 
Mitochondria (100ng/mL), isolated from SHSY-5Y, cells were incubated with 10u.g/mL of Bax either in the 
presence or absence of compound 22 or CoQ]0 in a reaction buffer and ROS generation was measured as described 
in Methods. ROS generated by Bax alone was taken as 100%. Compound 22 had a significant effect on lowering 
ROS generation at varying concentrations. Compound 22 (40uM) lowered levels by nearly 90% relative to the 
control. Fluorescence was monitored after 30min and read using the SpectraMax Gemini fluorescence plate reader 
and the standard error shown as error bars was calculated using Microsoft Excel program and the data obtained from 
six separate experiments. 
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Competitive Binding of 20uM Compound 9 and 22 in the 
Pesence of cy5.5-labelled sdAb5.2 
120 







sdAb alone w/ sdAb alone 
Bax w/o Bax 
cmpd 9 cmpd 22 
Figure 4.8: Blot binding assay: Compound 22 displays the ability to competitively bind to Bax in the 
presence of cy5.5-labeled sdAb5.2 
Following 30min of incubation with immobilized Bax and labelled sdAb, compound 22 effectively competed for 
binding spots on Bax. This is seen by the decrease (by 50%) in the amount of bound labelled sdAb, and reflected in 
•case (by 50%) in the unbound fraction of labelled sdAb. Compound 9 did not hav any effect on the amount 
iitd, labelled sdAb (still at 100%), and there was no change reflected in unbound fraction. Fluorescence was 
measured using a SpectraMax Gemini fluorescence plate reader. 
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a value of 97.968% ±1.3315% and the unbound fraction (34.965% ±3.0117%) was comparable 
to the unbound fraction of the Bax incubated alone with labelled sdAb (33.0466% ±11.984%). 
This confirmed that compound 9 was indeed nonspecific and did not compete with labelled sdAb 
for binding sites on Bax and that compound 22 was indeed competitively binding to bax in the 
presence of the labelled sdAb. 
4.9 In vivo Analysis of the Capability of Compound 22 to Prevent Apoptosis in Neuronal 
Cell Lines 
Following the in vitro analysis of the ability of compound 22 to bind to Bax at various 
concentrations, and lower the levels of Bax-induced mitochondrial ROS, it was necessary to 
monitor the capability of compound 22 to halt apoptosis due to exogenous oxidative stress. The 
intracellular environment that encompasses the mitochondria is quite different than isolated 
mitochondria that are treated on their own with Bax and compound 22, and thus the effect of 
compound 22 could be quite different inside the cell. This involved tracking particular hallmarks 
of apoptosis such as apoptotic cellular and nuclear morphology, plasma membrane flipping, loss 
of MMP, and protease activation. Mammalian cell lines were pretreated with compound 22 and 
then subjected to external oxidative stress and monitored over a specified period of time for signs 
of apoptosis. 
4.9.1 Monitoring Nuclear Morphology and Plasma Membrane Flipping 24h Following 
lOOuM H202 Treatment in SHSY-5Y Cells 
SHSY-5Y neuroblastoma cells were grown and treated with H2O2 treatment as described 
in the Methods section. As previously discussed, H2O2 causes oxidative stress leading to 
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apoptosis if the cell cannot act to detoxify it. Consequently, the cells were treated with lOOuM 
H2O2, which has been used in previous studies, to initiate oxidative-stress-induced apoptosis. 
After 24h cells were monitored for two particular signs of apoptosis: brightly stained, condensed 
nuclei made visible by Hoechst 33342 staining, and plasma membrane flipping made visible by 
Annexin V-FITC binding. Hoechst 33342 labels DNA by preferentially binding to A-T base 
pairs, allowing nuclei to become visible under UV light. Early during apoptosis, the membrane 
phospholipid phosphatidylserine (PS) flips from the inner to the outer leaflet of the plasma 
membrane. Once exposed to the extracellular environment, binding sites on PS become 
available for Annexin V, a phospholipid binding protein with a high affinity for PS. Annexin V 
can be conjugated to a fluorochrome such as FITC which allows for visualization under UV 
light. It can be seen in figure 4.9.1 A that the untreated control cells display both healthy nuclei 
and minimal Annexin V staining, which is typical for untreated cells. Control cells that were 
challenged with lOOuM H2O2 display a significant amount of cells with brightly stained 
condensed nuclei indicative of apoptosis, in addition to a considerable amount of plasma 
membrane flipping observed by the green stain of the Annexin V-FITC congugate. SHSY-5Y 
cells exposed to lOOuM H2O2 and 20uJM of nonspecific compound 9, displayed similar apoptotic 
features (brightly stained condensed nuclei and plasma membrane flipping) as cells treated with 
lOOuM H2O2 alone. This indicated that compound 9 did not offer any protection against H2O2-
induced apoptosis 24h-post treatment. Conversely, cells that were treated with lOOuM H2O2 and 
20uM of compound 22 remained resistant to apoptosis as indicated by the healthy nuclear 
morphology of the Hoechst stained cells, and the lack of plasma membrane flipping apparent in 
the Annexin V figures. 
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Quantitatively, cell counting (healthy vs. apoptotic nuclei) provided us with an idea of the 
percent cell viability in the different treatment groups 24h post-lOOuM H2O2. Five different 
fields were taken, and the percent cell viability was an average of the five different fields. It can 
be noted in figure 4.9.IB that untreated SHSY-5Y cells had a cell viability of 84.93%, whereas 
cells that were treated with lOOuM H2O2, and those treated with lOOuM H2O2 and compound 9 
possessed cell viability percentages of 52.74%, and 53.27% respectively. In contrast, cells that 
were challenged with lOOuM H2O2 and treated with compound 22 had a cell viability of 80.98%, 
which is comparable to the untreated cell population. 
4.9.2 Monitoring Nuclear Morphology and Plasma Membrane Flipping 48h Following 
lOOuM H202 Treatment in SHSY-5Y Cells 
SHSY-5Y cells were grown and treated in an identical manner as above, except the 
nuclear morphology and signs of membrane flipping were monitored 48h post-1 OOuM H2O2, as 
opposed to 24h. Similar results, both qualitatively, and quantitatively were observed at the 48h 
time point when compared to the 24h time point. SHSY-5Y cells that were treated with lOOuM 
H2O2 and non-specific compound 9 displayed brightly stained, condensed nuclei in addition to 
plasma membrane flipping 48h post treatment (comparable to cells challenged with lOOuM 
H2O2 alone) (figure 4.9.2A). Cells that were treated with lOOuM H2O2 and compound 22 had 
healthy nuclear morphology and no apparent plasma membrane flipping 48h post treatment as 
seen in figure 4.9.2A. 
Quantitatively, the cell viability that was observed 48h post-lOOuM H2O2 was similar to 
that of the 24h treatment as noted in figure 4.9.2B. However, the cell viabilities of the cells 
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treated with lOOuM H2O2, and those treated with lOOuM H2O2 and compound 9 possessed 
slightly lower cell viabilities of 46.52%, and 47.64% respectively. 
4.9.3 Mitochondrial ROS is Lowered by Compound 22 24h Post-lOOjiM H202 Treatment 
Since we observed that cells challenged with lOOuM H2O2 could be rescued from 
apoptosis by treatment with compound 22 (seen by the healthy nuclear morphology and absence 
of plasma membrane flipping), we wanted to examine the mitochondria for any change in levels 
of ROS. As discussed previously, excessive levels of mitochondrial ROS can lead to oxidative 
stress in the cell, leading to initiation of the apoptotic pathway. Increased levels of ROS can lead 
to DNA damage, p53 activation, followed by activation of Bax. Cells that were treated with 
lOOuM H2O2 have an increase in mitochondrial ROS and thus it was important to see if 
compound 22 was able to protect the cell from apoptosis by lowering the levels of mitochondrial 
ROS by inhibiting Bax. It is seen in figure 4.9.3 that mitochondria harvested from SHSY-5Y 
cells challenged with lOOuM H2O2 display a 40% increase in ROS when compared to the 
untreated control cells. Mitochondria isolated from cells that were treated with lOOuM H2O2 and 
a nonspecific compound (compound 9) display the same levels of ROS as cells challenged with 
lOOuM H202 alone, thus showing that it is not capable of diminishing the levels of ROS. 
Conversely, mitochondria harvested from cells that were treated with lOOuM H2O2 and 
compound 22 show levels of ROS comparable to the untreated control mitochondria alone 
(between 80-100 % relative fluorescence). 
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Figure 4.9.1 A: Nuclear morphology and plasma membrane flipping of SHSY-5Y cells 24h post lOOuM H202 
treatment 
Control cell lines that were untreated show predominantly healthy nuclear morphology, with minimal plasma — 
membrane flipping that reflected only normal amount of apoptosis. Control cell lines treated with lOOuM H2C<2 
show many brightly stained condensed nuclei made visible by Hoechst staining (white arrow) and significant plasma 
membrane flipping (Annexin V staining) indicated by the white arrow. Cells treated additionally with compound 9 
still display apoptotic nuclei and plasma membrane flipping, whereas cells treated additionally with compound 22 
do not and are comparable to control untreated cells. All fluorescent pictures were taken using an inverted stage 
fluorescence microscope (Magnification: 400x). 
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Viability of SHSY-5Y Cells 24h-post treatement 
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Figure 4.9.1B: Viability of SHSY-5Y cells 24h post-lOOuM H202 treatment 
24h following lOOuM H202 treatment, cultures were stained with Hoechst. Healthy and apoptotic nuclei from three 
separate experiments were counted using 5 fields/cell line/experiment, and the number of healthy cells was plotted 
as a percentage of all the cells counted as Cell Viability. SHSY-5Y cells that were treated with compound 22 show 
strong resistance to apoptosis, with cell viability values close to those of the untreated control cells (-80% cell 
viability). 
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Figure 4.9.2A: Nuclear morphology and plasma membrane flipping of SHSY-5Y Cells 48h post-lOOuM H202 
treatment 
Control cell lines that were untreated show predominantly healthy nuclear morphology, with no plasma membrane 
flipping. Control cell lines treated with lOOuM H202 show many brightly stained condensed nuclei made visible by 
Hoechst staining (white arrow) and significant plasma membrane flipping (Annexin V staining) indicated by the 
white arrow. Cells treated additionally with compound 9 still display apoptotic nuclei and plasma membrane 
flipping, whereas cells treated additionally with compound 22 do not and are comparable to control untreated cells. 
All fluorescent pictures were taken using an inverted stage fluorescence microscope (Magnification: 400x). 
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Viability of SHSY-5Y Cells 48h post-treatment 
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cmpd 9 cmpd 22 
Figure 4.9.2B: Viability of SHSY-5Y cells 48h post-lOOuM H202 treatment 
48h following lOOuM H202 treatment, cultures were stained with Hoechst. Healthy and apoptotic nuclei from three 
separate experiments were counted using 5 fields/treatment group/experiment, and the number of healthy cells was 
plotted as a percentage of all the cells counted as Cell Viability. SHSY-5Y cells that were treated with compound 
22 show strong resistance to apoptosis, with cell viability values close to those of the untreated control cells (-80% 
cell viability). 
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Figure 4.9.3: Mitochondrial ROS levels are lowered by compound 22 24h post-lOOuM H202 treatment 
SHSY-5Y cells treated with lOOuM H202 were harvested 24h later and the mitochondria were isolated. Levels of 
ROS were measured and expressed relative to the untreated control mitochondria. Compound 22 lowered 
mitochondrial ROS caused by lOOuM H202 to levels comparable to the untreated control mitochondria (~ 100% 
relative fluorescence). 
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4.9.4 Active Caspase 3 levels are Lowered by Compound 22 24h Post-lOOjiM H2O2 
Treatment 
In order to further examine the role of compound 22 in halting H^C^-induced apoptosis, 
the levels of Caspase 3 were monitored 24h following treatment. Caspase 3 is a pro-apoptotic 
protease involved primarily in the execution phase of apoptosis. As mentioned previously, it can 
be activated following release of Cytochrome c from the mitochondria, or through cleavage by 
Caspase 8. An assay based on the use of DEVD-AFC substrate can be used to determine the 
levels of active Caspase 3 fluorimetrically, as active Caspase 3 will cleave at the carboxy-
terminal of aspartic acid residues, thus releasing the AFC fluorophore which can be picked up by 
a fluorescence plate reader. Cells that are undergoing apoptosis will have increased levels of 
active Caspase 3; this result was noted fluorimetrically in the post-nuclear cytosolic fractions 
harvested form cells treated with lOOuM H2O2 (figure 4.9.4A). There was an increase of 66.54% 
in active Caspase 3 relative to the control untreated post-nuclear cytosol. This was reflected in 
the western blot of the post-nuclear cytosol for active Caspase 3 as seen in figure 4.9.4B, where 
there is an increase in intensity versus the control untreated. 
4.9.5 Cell Viability in Differentiated SHSY-5Y Cells treated with IOOJIM H202 
SHSY-5Y cells were differentiated as described in the methods section and challenged 
with lOOuM H2O2 for lh and monitored for signs of apoptosis 24h later. Since SHSY-5Y cells 
are neuronal precursor cells, it is important to observe the effects of compound 22 on fully 
differentiated neurons in determining its potential as a stroke therapeutic. Cells were monitored 
for signs of apoptosis by observing complete cellular morphology, nuclear morphology, the 
status of plasma membrane lipids, and lastly, A^V 
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4.9.5.1 Cellular Morphology of Differentiated Cells 24h Post-Treatment 
Differentiated SHSY-5Y cells that were challenged with lOOuM H2O2 were monitored 
for changes in their cellular morphology 24h post treatment. Healthy, differentiated neurons 
have cell bodies clustered together, with neurites projecting from them as seen in the untreated 
cells of figure 4.9.5.1. Differentiated cells that were observed 24 post-lOOuM H2O2 treatment 
appeared to have shrunken in size, have membrane blebbing, and apoptotitc bodies; all hallmarks 
of apoptosis (figure 4.9.5.1). Next, compound 22 and nonspecific compound 9 were tested for 
their ability to halt apoptotic events 24h following lOOuM H2O2. Cells that were treated alone 
with compound 9 do not display any morphological signs of apoptosis; however, when 
challenged with H2O2, the morphological signs of apoptosis are seen as in figure 4.9.5.1. Cells 
that were treated with compound 22 alone do not display cellular morphology associated with 
apoptosis, and in contrast to cells treated with compound 9 and lOOuM H2O2, those treated with 
compound 22 and lOOuM H2O2 display healthy cellular morphology comparable to the control 
untreated cells. 
4.9.5.2 Nuclear Morphology and Plasma Membrane Flipping of Differentiated Cells 24h 
Post-treatment 
Following the observation of the cellular morphology, differentiated SHSY-5Y cells were 
monitored by nuclear morphology and plasma membrane flipping. As noted with the 
undifferentiated SHSY-5Y cells, differentiated SHSY-5Y cells that were untreated display 
healthy nuclei indicated by lighter Hoechst staining and an oval shape (figure 4.9.5.2A). 
Differentiated cells that were challenged with lOOuM H2O2 exhibit brightly stained condensed 
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Figure 4.9.4: Post-nuclear cytosol isolated from cells challenged with lOOuM H 20 2 and treated with 
compound 22 display lower levels of active Caspase 3 similar to control, untreated cells 
SHSY-5Y cells treated with lOOuM H202 were harvested 24h later and the post-nuclear cytosol was isolated. 
Levels of active Caspase 3 were measured and expressed relative to the untreated control cytosol. Cytosol from 
cells that were treated with compound 22 displayed lower levels of active Caspase 3 (comparable to untreated 
control) than cytosol from cells treated with lOO^M H202 alone. 
95 
nuclei indicative of apoptosis, as well as plasma membrane flipping highlighted by Annexin V 
staining. As shown before, as well as in this case, cells challenged with lOOuM H2O2 and 
treated with compound 9 still have apoptotic nuclei and plasma membrane flipping, whereas 
those treated with compound 22 demonstrate healthy nuclei and a lack of plasma membrane 
flipping as visible in figure 4.9.5.2A. 
Cell viability was again quantified by counting dead and alive apoptotic nuclei with the 
population of untreated cells having a percent viability of 84.02% and those treated with lOOuM 
H2O2 possessed a cell viability of 50.83%. Cells that were challenged with lOOuM H2O2 and 
treated with compound 9 had a cell viability of 46.45%, whereas those treated with compound 22 
had 76.35% viable cells (figure 4.9.5.2B). 
4.9.5.3 Nuclear Morphology and Mitochondrial Membrane Potential of Differentiated Cells 
24h Post-treatment 
Another method of detecting apoptosis is by monitoring mitochondrial membrane 
permealization, utilizing JC-1 dye, which was performed in tandem with Hoechst staining. This 
will reveal whether cells that have lost their AT™, also possess apoptotic nuclei. As previously 
discussed, IM permeabilization involves the formation of pores or channels that cause the 
dissipation of the A*Fm established across the IM. Lipophilic cations accumulate in the 
mitochondrial matrix, driven by &Wm. Since the A^m ranges from 120 to 180mv in 
physiological conditions (the intramitochondrial side is electronegative), the concentration of 
cations is normally 2 to 3 logs higher in the mitochondrial matrix than in the cytosol. Due to 
this, different cationic flurochromes can be utilized to measure the A^m (Castedo, et al, 2002; 
Metivierttfa/., 1998). 
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Untreated Treated 100p.lVl H202 
Untreated, treated cmpd 9 Treated lOO^M H202, t reated cmpd 9 
Untreated, treated 20|aM cmpd 22 Treated 100p.M H202, treated 20nM cmpd 22 
Figure 4.9.5.1: Differentiated SHSY-5Y cells treated with 20uM compound 22 display healthy cellular 
morphology following exposure to lOOuM H2Oj 
SHSY-5Y cells were differentiated into neurons as described in Methods and cell morphology was monitored 24h 
following lOOuM H202 treatment. Untreated cells, cells treated with compound 9 or 22 alone, or a combination of 
lOOuM H202 and compound 22, show healthy morphology and neurites. Cells that were treated with lOOuM H202> 
or a combination of lOOuM H202 and compound 9 display condensed, shrunken morphology with membrane 
blebbing consistent with apoptosis. (Magnification: 400x). 
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Figure 4.9.5.2A: Differentiated SHSY-5Y cells treated with 20uM compound 22 display healthy nuclear 
morphology and lack plasma membrane flipping 24h following exposure to lOOuM H202. 
Untreated control cells show predominantly healthy nuclear morphology, with minimal plasma membrane flipping. 
Control cell lines treated with lOOuM H202 show many brightly stained condensed nuclei made visible by Hoechst 
staining (white arrow) and significant plasma membrane flipping (Annexin V staining) indicated by the white arrow. 
Cells treated additionally with compound 9 still display apoptotic nuclei and plasma membrane flipping, whereas 
cells treated additionally with compound 22 do not and are comparable to control untreated cells. All fluorescent 
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Figure 4.9.5.2B: Quantifying cell viability of differentiated SHSY-5Y cells 24h following lOOuM H202 
treatment. 
24h following lOOuM H202 treatment, cultures were stained with Hoechst. Healthy and apoptotic nuclei from three 
separate experiments were counted using 5 fields/treatment group/experiment, and the number of healthy cells was 
'ntted as a percentage of all the cells counted as Cell Viability. SHSY-5Y cells that were treated with compound 
..: show strong resistance to apoptosis, with cell viability values close to those of the untreated control cells (~80% 
cell viability). 
99 
One such fluorochrome, 5, 5', 6, 6'-tetrachloro-l, V, 3, 3'-tetraethylbenzimidazolcarbocyanine 
iodide (JC-1), emits green and/or red according to its oligomerization status. JC-1 incorporates 
into mitochondria where it either forms monomers (emitting green, at 527nm), or at higher dye 
concentrations (indicating a high A^m), forms aggregates (emitting red, at 590nm). Thus, the 
ratio between green and red JC-1 fluorescence provides an estimate of &Wm that is (relatively) 
independent of the mass of mitochondria. Mitochondria that have lost their A^m, will not be 
able to form aggregates and will not stain brightly red, but will only fluoresce green. 
As seen in figure 4.9.5.3, cells that were not subjected to lOOuM H2O2 treatment retain 
the red JC-1 stain indicating the presence of ÂPm in addition to having a healthy nuclear 
morphology indicated by Hoechst staining. Cells that were challenged with lOOuM H2O2 still 
show some green JC-1 staining, however the red aggregate staining was significantly diminished 
(figure 4.9.5.3), indicating a loss of AY™; Hoechst staining indicates these cells possess apoptotic 
nuclei. The same outcome is seen with cells that were treated with lOOuM H2O2 as well as with 
nonspecific compound 9: there is a decrease in red JC-1 staining, and positive apoptotic nuclei. 
Lastly, cells treated with both lOOuM H2O2 and compound 22 display red punctate JC-1 
fluorescence, indicating maintenance of Â Pm, and healthy nuclear morphology shown by 
Hoechst staining. 
4.9.6 Cell Viability of NT-2 Cells Treated with IOOJIM H202 
To further characterize the ability of compound 22 to interact with Bax inside the cell and 
halt oxidative stress-induced apoptosis, it was important to observe the effects of compound 22 
in an alternative cell line. The NT-2 (or N Tera 2) cell line is a neuronally-committed human 
teratocarcinoma, and like the the SHSY-5Y cell line, possesses the ability to be differentiated 
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into neurons. NT-2 cells challenged with lOOuM H2O2 and treated with 20uM compound 22 
were monitored for changes to nuclear morphology and plasma membrane composition for signs 
of apoptosis. 
4.9.6.1 Nuclear Morphology of NT-2 Cells 24h Post-lOOuM H202 Treatment 
The NT-2 cells that were monitored 24h post-lOOuM H2O2 treatment displayed similar 
nuclear morphology as the SHSY-5Y cells under the same conditions. NT-2 cells treated with 
lOOuM H2O2 and compound 9 display no resistance to apoptosis, having brightly stained 
condensed nuclei, whereas those treated with lOOuM H2O2 and compound 22 show significant 
resistance to apoptosis and display healthy nuclei (figure 4.9.6.1 A). 
Additionally, the NT-2 cell viability 24h following treatment was comparable to that of 
the SHSY-5Ys, with cell viabilities of untreated, lOOuM H202-treated, lOOuM H202 and 
compound 9 treated, and lOOuM H2O2 and compound 22 treated were determined to be 82.20%, 
54.53%, 54.40%, and 78.64% respectively (figure 4.9.6.1B). 
4.9.6.2 Nuclear Morphology of NT-2 Cells 48h Post-1 OOuM H2Oz Treatment 
The NT-2 cells that were monitored 48h post-lOOuM H2O2 treatment displayed similar 
nuclear morphology as the SHSY-5Y cells under the same conditions. Those treated with 
lOOuM H2O2 and compound 9 display no resistance to apoptosis, having brightly stained 
condensed nuclei, whereas those treated with lOOuM H2O2 and compound 22, show resistance to 
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Figure 4.9.5.3: Mitochondrial membrane potential and nuclear morphology of differentiated SHSY-5Y cells 
24h following lOOuM H202 treatment 
SHSY-5Y cells were differentiated as described in the Methods and subjected to lh of lOOuM H202 treatment. 24h 
following treatment, cells treated with lOOuM H202 and compound 9, display a loss of A*Pm indicated by the loss of 
red staining (white arrow) combined with apoptotic nuclear morphology. Cells treated with lOOuM H202 and 
compound 22 retain ATra indicated by the red JC-1 staining, and possess healthy nuclei made visible by the Hoechst 
staining. (Scale unit: 100 microns). 
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Figure 4.9.6.1 A: Nuclear morphology of NT-2 cells 24h following lOOuM H202 treatment 
NT-2 cells treated with lOOuM H202 and compound 9 display apoptotic nuclei, whereas NT-2 cells treated with 
lOOuM H202 compound 22 have healthy nuclei comparable to control untreated cells. All fluorescent pictures were 
taken using an inverted stage fluorescence microscope (Magnification: 400x). 
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Figure 4.9.6.1B. Quantifying viability of NT-2 cells 24h following lOOuM H202 treatment. 
24h following lOOuM H202 treatment, NT-2 cultures were stained with Hoechst. Healthy and apoptotic nuclei from 
three separate experiments were counted using 5 fields/treatment group/experiment, and the number of healthy cells 
was plotted as a percentage of all the cells counted as Cell Viability. NT-2 cells that were treated with compound 




Additionally, the NT-2 cell viability 48h following treatment was comparable to that of 
the SHSY-5Ys, with cell viabilities of untreated, lOOuM H202-treated, lOOuM H202 and 
compound 9 treated, and lOOuM H202 and compound 22 treated were determined to be 82.10%, 
47.85%, 49.20%, and 79.84% respectively (figure 4.9.6.2B). 
4.9.7 Monitoring Cell Viability of SHSY-5Y Cells Following Hypoxia/Hypoglycemia-
Induced Oxidative Stress 
Hypoxia/hypoglycemia was induced in cells treated with either non-specific compound 9 
or compound 22 for 12h as described in the Methods section. After 12h, the cells were rescued 
by culturing them in nutrient-supplemented media and re-exposing them to oxygen. The cells 
were then monitored for signs of apoptosis by observing their nuclear morphology via Hoechst 
staining and plasma membrane flipping via Annexin V staining (figure 4.9.7A). Cell viability 
was again determined by counting Hoechst-stained nuclei and determining the total percent 
viability. 
This hypoxia/hypoglycemia experiment was assumed to be a close model for 
investigating the damage caused by reperfusion of blood after suffering a stroke. As discussed, 
there is a marked increase in ROS during reperfusion, which can spread to surrounding healthy 
neurons, leading to over-activation of Bax, ultimately leading to inappropriate induction of 
apoptosis in these cells. Thus, we monitored the ability of compound 22 to inhibit Bax under 
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Figure 4.9.6.2A: Nuclear morphology of NT-2 cells 48h following lOOuM H202 treatment. 
NT-2 cells treated with lOOuM H202 and compound 9 display apoptotic nuclei, whereas NT-2 cells treated with 
lOOuM H2O2 compound 22 have healthy nuclei comparable to control untreated cells. All fluorescent pictures were 
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Figure 4.9.6.2B: Quantifying viability of NT-2 Cells 48h following lOOuM H202 treatment. 
48h following lOOuM H2O2 treatment, NT-2 cultures were stained with Hoechst. Healthy and apoptotic nuclei from 
three separate experiments were counted using 5 fields/treatment group/experiment, and the number of healthy cells 
was plotted as a percentage of all the cells counted as Cell Viability. NT-2 cells that were treated with compound 
22 show strong resistance to apoptosis, with cell viability values close to those of the untreated control cells (-80% 
cell viability. 
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It was observed after 12h of hypoxia/hypoglycemia, that cells that were additionally 
treated with 20|iM of compound 9, still display brightly stained condensed nuclei and plasma 
membrane flipping indicative of apoptosis. Conversely, cells that were additionally treated with 
20uM of compound 22 display healthy nuclei and lack plasma membrane flipping (figure 
4.9.7A). The determined cell viability was in accordance with the observed nuclear morphology 
and plasma membrane flipping; cells additionally treated with compound 22 had a percent 
viability close to that of the untreated control (figure 4.9.7B). 
4.9.8 Proliferation of SHSY-5Y Cells Following lOO^M H202 Treatment 
We observed that cells treated with 20uM compound 22 were resistant to apoptosis 
induced by exposure to lOOuM H2O2 through cellular staining techniques and measurement of 
active Caspase 3 and ROS level, so we wanted to ensure that this resistance to apoptosis was not 
at the expense of other cellular mechanisms like cell division. Thus, we monitored SHSY-5Y 
cells for up to 10 days following lOOuM H2O2 exposure. Cells were divided into four treatment 
groups: untreated, treated lOOuM H2O2, treated lOOuM H2O2 and compound 9, and treated 
lOOuM H2O2 and compound 22. The four groups were split evenly from a common stock of 
cells to ensure that each group started with approximately the same cell number. Once the cells 
reached 70-80% confluence, the appropriate treatments were performed. Forty-eight hours 
following treatment, the cells were counted using Trypan Blue, replated and then counted again 
on day 5, and on day 10 to record a growth curve for each treatment group. In figure 4.9.8, it can 
be noted that the untreated cells and those treated with both lOOuM H2O2 and compound 22 had 
comparable rates of proliferation with a population doubling of slightly less than 48h (the normal 
population doubling time for SHSY-5Y cells). Cells that were treated with lOOuM H2O2 or 
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Figure 4.9.7.1A: Nuclear morphology and plasma membrane flipping in SHSY-5Y cells following 
hypoxia/hypoglycemia (h/h) 
Control cell lines that were untreated show predominantly healthy nuclear morphology, with no plasma membrane 
flipping. Control cell lines placed under hypoxia/hypoglycemia show many brightly stained condensed nuclei made 
visible by Hoechst staining (white arrows) and significant plasma membrane flipping (Annexin V staining) indicated 
by the white arrows. Cells treated additionally with compound 9 still display apoptotic nuclei and plasma 
membrane flipping, whereas cells treated additionally with compound 22 do not and are comparable to control 
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Figure 4.9.7.1B: Quantifying viability of SHSY-5Y cells following hypoxia/hypoglycemia 
12h following hypoxia/hypoglycemia, cell cultures were stained with Hoechst. Healthy and apoptotic nuclei from 
three separate experiments were counted using 5 fields/treatment group/experiment, and the number of healthy cells 
was plotted as a percentage of all the cells counted as Cell Viability. Cells that were treated with compound 22 
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Figure 4.9.8: Proliferation of SHSY-5Y cells following lOOuM H202 exposure. 
Cell division was monitored by counting live cells using Trypan Blue, starting at 48h after lOOuM H202 (lh) 
treatment. Cells treated additionally with compound 22 underwent slightly under two division cycles from 5d to 
lOd, which is in agreement with the doubling rate of SHSY-5Y. Cells additionally treated with compound 9 were 
not able to divide normally following lOOuM H202 exposure, and the population of cells slightly decreased between 
"̂d to lOd. 
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Figure 4.9.9: Levels of H202 are not directly quenched by compound 22 
When lOOuM H202 was incubated alone with SHSY-5Y cell media, there was a 6 fold increase in relative 
fluorescence intensity when compared to media alone (measured using Amplex Red). When compound 22 was 
added, there was no change in relative fluorescence after 30min and 3h of incubation. This means that compound 
22 itself is not directly quenching H202 before it can enter the cell and cause oxidative stress. 
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4.9.10 Preliminary Study of the Cellular Uptake of Compound 22 
To investigate the cellular uptake of compound 22, its unique absorbance peak in the 
visible spectra was taken advantage of. Following a wavelength scan beginning a 250nm and 
going to 700nm, compound 22 was found to have an absorbance peak at 425nm (see figure 
4.9.10A). The media that was used to grow the SHSY-5Y cells was found to have an absorbance 
peak at around 230nm, and so the presence of compound 22 could be monitored in the media. 
Additionally, a standard concentration curve was developed for compound 22 so that the specific 
concentration found in the media following predetermined incubation times could be calculated 
(figure 4.9.1 OB) and the molar extinction coefficient was also found to be on average, 
22,070M"1cm"1. 
It was found after 18h of incubation that media incubated with 20 uM of compound 22 
alone had 10.9uM left. This meant that perhaps there was some degradation of compound 22 or 
its absorbance was quenched by binding to serum proteins of the media over the 18h. However, 
when SHSY-5Y cells were present in the dish, only 2.46uM of compound 22 remained in the 
media, indicating that some could be entering the cell over 18h (figure 4.9.IOC). 
Lastly, when a wavelength scan from 400nm-500nm was performed on isolated post-
nuclear cytosol, it was noted that there was no significant absorbance peak (it hovered around 
0.100). However, when 20uM of compound 22 was incubated with the post-nuclear cytosol, a 
clear absorbance peak could be seen around 425nm with a value of 0.649. This could be useful 
in the future for determining the relative amount of compound 22 in particular subcellular 
components of the cell; however this work is still preliminary. 
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Figure 4.9.10A: Absorption profile of compound 22 
By performing a wavelength scan of absorption from 250nm-700nm (only 250-550nm is shown here), we 
determined that the absorption peak of compound 22 occurs at 425nm. In this case 80um of compound 22 was used 
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Figure 4.9.10B: Absorption at 425nm of varying concentrations of compound 22 
The relationship between absorption and concentration of compound 22 was found to be linear and can be used to 
determine various concentrations of compound 22 present in the media surrounding cells. This can be used to see 
how much compound 22 is taken into the cell over a specified time period. 
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Figure 4.9.1 OC: Concentration of compound 22 remaining in the media following 18h incubation 
Initially, 20uM of compound 22 was added to both media alone, and media surrounding SHSY-5Y cells. Eighteen 
hours later there was a decrease in the concentration of compound 22 in both the media alone and the media with 
cells. However, the decrease in compound 22 was significantly more in the media surrounding cells than in the 
media incubated with compound 22 alone. This indicated that perhaps the cells are indeed taking in compound 22. 
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Figure 4.9.10D: Absorption profile of post-nuclear cytosol incubated with and without compound 22 
An absorbance scan between 400nm-500nm was performed on 10|ig/mL of post-nuclear cytosol alone or incubated 
with 20uM compound. It was noted that only post-nuclear cytosol incubated with compound 22 had a significant 
peak at 425nm. 
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4.9.11 Preliminary Investigation of the effect of Compound 22 on the Interaction of Bax 
with VDAC 
We observed that compound 22 was capable of protecting mitochondria from Bax-
induced permealization, so we wanted to understand if perhaps compound 22 was binding to Bax 
at its VDAC interaction site, and preventing Bax-induced opening of the mitochondrial PTP. 
Using mitochondria isolated from untreated SHSY-5Y cells, lOOuM H^C^-treated cells, and 
lOOuM H2C>2-treated cells treated with either compound 9 or 22, we performed 
immunoprecipitation using anti-VDAC antibodies and protein G-Sepharose beads as described in 
the methods. From previously published results as well as work performed in our laboratory, 
Bax is known to interact with VDAC, and can be co-precipitated using anti-VDAC or anti-Bid 
antibodies bound to protein G-Sepharose resin (Gueorguieva et al, 2006). Utilizing this 
information, we hypothesized that if compound 22 was interacting with Bax at the VDAC 
binding site, the presence of compound 22 would prevent Bax-VDAC interaction, which could 
be monitored by immunoprecipitation, followed by SDS-PAGE and Western Blot. Indeed, a 
decrease in Bax was observed by preliminary Western blot analysis in mitochondrial fractions 
isolated from cells that were treated with lOOuM H2O2 and compound 22 versus compared to 
those treated with lOOuM H2O2 alone (data not shown). 
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Chapter 5: Discussion 
Part 1 
In this study we have identified a novel manner of both quenching and increasing the 
activity of Caspase 3. This study considered the ability of two Caspase 3-specfic VHHS to 
modulate the activity of isolated Caspase 3 as well as within SHSY-5Y cells via transient 
transfections. The VhhCasp31 was capable of inhibiting the activity of Caspase 3, whereas 
VhhCasp32 enhanced Caspase 3 activity. Moreover, VhhCasp31 and VhhCasp32, respectively, 
inhibited and accelerated apoptosis when expressed as intrabodies in mammalian cells. These 
anti-Caspase 3 VHHS have important potential as models for identifying small molecular weight 
modulators that can mimic the action of the VHHS described above. These small molecular 
weight mimetics could be used for possible treatment of neurodegenerative diseases or cancer 
involving Caspase 3 activation. 
5.1 Targeting Caspase 3 as a mean of inhibiting oxidative stress induced apoptosis 
Caspase 3 was chosen as a target for to modulate apoptosis, as it is one of the most 
common executioners of apoptosis (Denault, et al, 2002). Caspase 3 is also activated by both 
intrinsic and extrinsic pathways of apoptosis, with the ability to be cleaved by both Caspase 8 
and the Caspase 9-APAF-l complex, meaning that it can become activated by ligand signalling 
from the plasma membrane as well as signalling from the mitochondria. Caspase 3, as an 
executioner caspase, plays a role in mediating the cleavage of ICAD, the inhibitor of CAD, 
which is responsible for DNA degradation and Caspase 3 is one of the last checkpoints in the 
pathway toward DNA degradation, and subsequent apoptosis, thus making it an important target 
for modulating of the apoptotic pathway (Lee, et al, 2000a). 
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Caspase 3 has been shown to be important for survival, as Caspase 3 knockout mice are 
born at low frequency and die after only a few weeks. A striking characteristic of these mice are 
skull defects with ectopic masses of supernumerary cells that represent the failure of apoptosis 
during the development of the brain, but surprisingly, not in other organs or tissues (Kuida et al, 
1996 and Woo et al, 1998). Thus, Caspase 3 acts in a tissue selective manner early in 
development with two possible explanations. There may be a shortage of crucial caspase 3-like 
proteases that can substitute for Caspase 3 at a crucial stage in the neuronal apoptosis program, 
or Caspase 3 may lie at the heart of an essential neuronal apoptotic pathway. 
The pivotal role of caspase 3 in neuronal apoptosis is highlighted again when examining 
cell death mechanisms in neurodegeneration. Particularly, it has been found that Caspase 3 
activity is induced by reperfusion in the ischemic core and penumbra after stroke in neonates 
(Manabat et al, 2003). Recent evidence has suggested that although some Caspase 3-dependent 
cell death occurs in the adult brain after ischemia, caspase-dependent death is quite prominent in 
the neonatal brain after hypoxia and ischemic insults, including hypoxia-ischemia (Cheng et al, 
1997; Ferrer et al, 1997; Han et al, 2000). This presents an interesting, relevant focus for 
therapeutic targeting of Caspase 3 following ischemic stroke. 
The role of Caspase 3 has been studied thoroughly in cancer models, in particular breast 
cancers, and other caspase-3 deficient cancer cell lines such as certain ovarian and cervical cell 
lines. Approximately 75% of the tumour as well as morphologically normal peritumoral tissue 
samples lacked the caspase3 transcript and caspase 3 protein expression. Additionally, the 
caspases3 mRNA levels in commercially available total RNA samples from breast, ovarian, and 
cervical tumours were either undetectable (breast and cervical) or substantially decreased 
(ovarian). Despite the complete loss of caspase-3, the expression levels of other caspases, such 
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as caspase 8 and caspase 9, were normal in all the tumour samples studied (Devarajan et ah, 
2002). These results suggest that the loss of caspases3 expression may represent an important 
cell survival mechanism in patients with these forms of cancer and highlights the importance of 
normal caspase 3 expression in proper cell homeostasis. Although, a caspase 3-targeting 
therapeutic would not be of much use in caspase 3-deficient cancers, it has a relevant role in 
targeting cancers where caspase 3 is present but not activated properly from upstream 
modulators. 
5.2 Using Single domain antibodies to modulate Caspase 3 activity 
As previously discussed, unlike the larger human antibodies such as IgG, the camelid 
species such as llamas camels have antibodies that consist of only variable heavy chains (VRHS). 
The absence of the light chains allow researchers to isolate a smaller antigen binding active 
complexes termed single domain antibodies (sdAbs), which are at least half the size of the scFvs 
isolated from conventional IgGs. These particular antibodies are advantageous for intracellular 
studies, compared to the scFvs due to their smaller size and greater solubility. Additionally, sdAbs have 
antigen combining sites that consist of only the three CDRs of the heavy chain variable domain 
(Tanha et al, 2002). The CDR3, however, makes the most antigen contacts and molecular 
interactions in the antibody combining sites (Padlan, 1994). Through isolation and amplification 
of only these specific antigen binding regions, we can select a low molecular weight peptide 
fragment that possess very specific and strong bindng affinities for the antigen of interest, such 
as caspase 3. 
In addition, by utilizing a llama phage display library, the specific gene for the antibody 
against the antigen is individually cloned into a phage which will express the desired antibody on 
its surface. Thus by panning, we can isolate both the specific sdAb for a particular antigen 
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(displayed on the phage surface) as well as the gene. Utilizing this particular panning assay, we 
have isolated two unique sdAbs against Caspase 3 as well as their respective genes. 
Subsequently, this allowed us to study the sdAbs in two ways: in vitro to test their efficacy at 
modulating Caspase 3 activity and intracellular^ via transient transfection. The former "in vivo" 
approach allowed us to study the sdAbs as intrabodies, and observe if they can modulate 
apoptosis. 
5.3 Specificity and efficacy of anti-Caspase 3 VHHS in modulating Caspase 3 function in 
vitro 
We were able to show in vitro that Vhhcasp31 was capable of lowering the activity of 
Caspase 3 and VhhCasp32 was able to increase the activity in a concentration-dependent 
manner. Importantly, when Caspase 3 was treated with an irrelevant VHH, Vhh5.2, under both 
concentration conditions, Caspase 3 demonstrated negligible changes in activity, thus ruling out 
the possibility that the modulating effects of VhhCasp31 and VhhCasp32 might be non-specific. 
The initial Caspase 3 concentration of 4.7uM was chosen because this was the lowest 
concentration of active Caspase 3 that produced a significant amount of fluorescence when 
compared to a control well contain buffer and DEVD-AFC peptide alone. In the future, the 
effect VhhCasp31 and VhhCasp32 on Caspase 3 binding could be monitored kinetically to 
determine, for example, the saturation point, rate of reaction, Km, and Kj. 
A previous study performed by Lee et al. in 2000 identified selective inhibitors for both 
Caspase 3 and 7, and have suggested that blocking these two caspases alone within the cell is 
sufficient for blocking apoptosis (Lee et al., 2000a). Thus, it was important in our study to not 
only consider the effects of VhhCasp31 and VhhCas32 in vitro, but extend this approach to the 
cellular level in order to evaluate the efficacy of the antibodies in halting apoptosis in vivo. 
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5.4 Anti-Caspase 3 VHHs are specific inhibitors of the Caspase 3-associated apoptotic 
pathway 
Transient transfections were performed to evaluate the ability of the VHHS to quench the 
activity of Caspase 3 (activated by oxidative stress) by VhhCasp31 and to increase the activity of 
Caspase 3 by VhhCasp32 within the cells. Applying the VHHS directly to active Caspase 3 
isolated from cellular lysate does allow for observation into the modulating abilities of the VHHS, 
however, expression of the VHHS intracellularly takes into account factors present in the cell that 
may affect the ability of the VHHS to modulate Caspase 3 activity. The VHHS may have different 
effects within the cells when compared with their actions outside of the cell. For example, the 
VHHS could prove to be toxic to the cell, may not be expressed at all, and may either show 
prevention of apoptosis, acceleration of apoptosis, or no protection from apoptosis. Even though 
the VHHS may show specificity toward Caspase 3, it may not show beneficial alterations within 
the cell, or even cause problems with other metabolic pathways within the cell. 
The VHHS may have altered the activity of Caspase 3 by binding to (i) the active site of 
Caspase 3, preventing its catalytic function, (ii) different subunits, preventing them from 
dimerizing, hence preventing procaspase 3 from becoming active, (iii) a site on procaspase 3 that 
enhances the cleavage and subsequent dimerization, thus boosting activity and (iv) a site on 
Caspase 3 that results in conformational changes leading to inactivation (by VhhCasp31) or 
enhancement (by VhhCasp32) of Caspase 3 activity. 
SHSY-5Y cells were used as a model in this study to show prevention of cell death in 
regards to neurodegenerative disease. SHSY-5Y cells have the ability to be differentiated into 
neuronal cells, making them a good choice for qualitatively observing the effects of oxidative 
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stress, and the abilities of the VHHS to affect cell death via transient transfections (McCarthy et 
al., 2004; Gueorguieva et al, 2006); this "transienf'model, however, provides only qualitative 
data. Using stably transfected, SHSY-5Y cell lines which permanently express the VHH genes 
one could obtain quantitative data such as apoptotic index. Additionally, stably-transfected, 
VHH-expressing SHSY-5Y cells could be differentiated into neuronal cells which are closer a 
model to neurons in neurodegenerative disease. 
Part2 
In this study, we screened a 34-member pharmacaphore library of biologically active low 
molecular weight compounds for those that could bind to Bax in the same manner as an anti-Bax 
VHH (sdAb) previously identified by our group to block Bax function under oxidative stress. We 
found one particular compound, "compound 22," that was capable of binding to and blocking 
Bax function in vitro (thus lowering levels of mitochondrial ROS) as well in vivo (using a 
neuronal cell-based model). Neuronal cells treated with compound 22 are virtually resistant to 
oxidative-stress-induced apoptosis and are able to divide normally following oxidative stress. 
Additionally, compound 22 was found to be taken in by the cells through spectrophotometric 
analysis and does not quench H2O2 before it can enter the cell and initiate oxidative stress. This 
finding has important implications in the development of therapies for neurodegenerative 
diseases. 
5.5 Targeting Bax as a means to inhibit oxidative stress induced apoptosis 
When considering methods of blocking oxidative-stress-induced apoptosis, particularly in 
the post-mitotic neurons of the brain, we chose to target Bax protein due to the important role it 
plays in intrinsic apoptotic signal transduction via the mitochondria (Wolter et al, 1997). 
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Following activation, Bax is understood to translocate from the cytosol to the MOM, where is 
inserts itself and interacts with the permeability transition pore. In particular, Bax is thought to 
associate with VDAC, a component of the PTP, causing the rupturing of the mitochondrial outer 
membrane (MOM) and release of various pro-apoptotic proteins such as Cyt c, which can lead to 
subsequent cell death. 
Bax becomes an important target for development of treatments for neurodegeneration, as 
the activity of Bax is increased in the presence of ROS, leading to the inappropriate induction of 
apoptosis due to oxidative damage. Specifically, in ischemia/reperfusion, levels of ROS become 
elevated causing DNA damage and in turn rapid p53 upregulation, which in turn can mediate 
apoptosis through transcription of Bax (Culmsee etal, 2007). 
In a study by Chi-Hsin et al, in 2005, it was shown that Bax translocation could be 
blocked by an anti-apoptotic drug furosemide, and neuronal cell death due to ischemia could be 
prevented (Chi-Hsin et al, 2005). Furthermore, elevated levels of Bax have also been shown to 
be present in the l-Methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's 
model. MPTP causes damages dopaminergic neurons in the substantia nigra pars compacta 
(SNpc) as seen in Parkinson's disease. This group showed that Bax was highly expressed in the 
SNpc and in adult mice, and there was an up-regulation of Bax in the SNpc after MPTP 
administration and a decrease in Bcl-2. Additionally, they found that mutant mice lacking Bax 
were significantly more resistant to MPTP than their wild-type littermates (Vila et al, 2000). 
This study demonstrates that Bax plays a critical role in the MPTP neurotoxic process and 
suggests that targeting Bax may provide protective benefit in the treatment of Parkinson's 
disease. 
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Additionally, it has been shown that the deletion of Bax in mice increases the resistance 
to ischemic insults (Hertz et al, 2005). Further evidence for the crucial role of Bax in neuronal 
cell death was provided by a study showing that cerebellum granule neurons are protected 
against prion-induced apoptosis in Bax" mice (Chiesa et al, 2005). Bax"" mice/gerbils are 
viable (as compared to Caspase 3'" mice) and provide a valuable means to study the specificity 
of a particular inhibitor for Bax. For example, in a study by Hertz et al, (2005), neurons from 
Bax"A gerbils that were treated with a Bax channel inhibitor show no protection from ischemia. 
Alternatively, neurons from wildtype litermates treated with the Bax channel inhibitor display 
protection from ischemia (Hertz et al, 2005). However, this inhibitor of Bax channel formation 
would only be administered temporarily to reduce tissue damage following ischemic injuries in 
the brain. Either Bax or Bak protein is required for MOMP to occur, however, permanent 
inhibition of Bax function in the adult brain could lead to a reduction in overall desirable 
apoptosis to eliminate damaged cells that are required to die (Wei, et al., 2001). This is turn 
could tip the balance of cell death survival in favour of the development of cancer. In particular, 
endogenous Bax inhibitors such as Bax Inhibitor-1 have been shown to be upregulated in 
aggressive cancers such as prostate (Grzmil et al, 2003). 
5.6 Using a pharmacaphore library of small molecular weight compounds to inhibit 
Bax activity 
In the search for avenues of modulating the activity of a protein of interest, an area that 
has recently received much focus is the utilization of small molecular-weight compounds capable 
of modulating protein-protein interaction, and subsequently protein activity. The Bcl-2 family of 
proteins has been given much attention of the last several years as targets for small-molecule 
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modulators (Becattini et al, 2006; Degterev et al, 2001; Enyedy et al, 2001; Oltersdorf et al, 
2005; and Wang et al, 2000). Small-molecule inhibitors are more stable than peptide inhibitors, 
are cell peremeable, and less immunogenic than their peptide counterparts. This is an important 
consideration when in search for possible therapeutics for neurodegeneration, as passage through 
the blood-brain barrier is tightly regulated. 
When looking for small-molecule inhibitors that could bind to Bax, there are two specific 
regions that could be considered for targeting. One such region is the BH3 domain (helix a2), 
which is used for both homodimerization and heterodimerization with other members of the Bcl-
2 family. Another region to consider is a portion C-terminal hydrophobic region of Bax, the 
putative transmembrane domain, which composes helix a9. The helix a9 of Bax is located in the 
hydrophobic pocket, bound to the BH3 domain, when present in the cytosol. Upon activation, 
the helix a9 disengages from the BH3 domain and is thought to insert into the MOM 
(Nechushtan et al, 1999). 
In our present study of screening pharmacaphore libraries for small molecular weight 
compounds that can bind to pro-apoptotic Bax in the same manner as the labelled anti-Bax sdAb 
and block its function, we screened 34 small molecules from the same commercial library that 
was utilized by a group that found inhibitors of the Bcl-XL/Bak-BH3 interaction One of these 
compounds was the BH3I-1 inhibitor itself, and the remaining 33 were derivatives of BH3I-1. 
Since Bax has a BH3 domain, and BH3I-1 disrupts the BH3 domain of Bak from interacting with 
the hydrophobic cleft formed by the BH1, BH2 and BH3 domains of BCI-XL (Degterev et al, 
2001), we proposed that perhaps these derivatives of BH3I-1 could bind to the BH3 domain of 
Bax, thus blocking its homodimeration or heterodimerization with other Bcl-2 family members, 
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or preventing the disengagement of ahelix 9 from the BH3 domain, thus preventing subsequent 
loss of AYm and apoptosis. 
5.7 Specificity of the binding of compound 22 to Bax protein and lowering of ROS levels 
Of the 34 small molecular weight compounds, nine were found to be capable of 
competitively binding to Bax protein in the presence of cy5.5-labelled sdAb5.2. The sdAb5.2 
was selected from six previously screened anti-Bax sdAbs that were all capable of preventing 
Bax-induced mitochondrial ROS as well as protecting cells from oxidative-stress induced 
apoptosis. However, sdAb 5.2 was found to have the greatest ability to lower levels of Bax-
induced ROS and inhibit oxidative-stress-induced apoptosis, and thus was chosen for fluorescent 
cy5.5 labelling (Gueorguieva et al, 2006). We performed a competitive binding assay because 
we wanted to find a small molecular weight compound that was able to bind to Bax in the same 
manner as the labelled anti-Bax sdAb, meaning that it would be highly specific. We found that 
compound 22 was quite effective at competitively bind to Bax in the presence of labelled 
sdAb5.2, and thus tested compound 22, along with a non-specific compound, compound 9 on 
their ability to competitively bind to Bax through an alternative binding assay. In this second 
binding assay, Bax was immobilized on nitrocellulose paper, thus ensuring that Bax would not 
be dislodged from the bottom of a coated well and float in the supernatant where labelled sdAb 
could still be binding to Bax, thus skewing the fluorescence reading of the supernatant. It was 
shown again through this method that compound 22 was able to competitively bind to Bax in the 
presence of labelled sdAb5.2, whereas nonspecific compound was again unable to competitively 
bind to Bax. 
While the specificity for binding to Bax was determined for each compound, the compounds 
were also tested on their ability to lower the levels of Bax-induced ROS in isolated mitochondria. 
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Although the exact mechanism of Bax-induced mitochondrial membrane permealization is still 
under debate, it has been well documented that presence of Bax does indeed cause A^m collapse 
resulting in elevated ROS generation and release (Adachi et al, 2004; Halestrap et al, 2002; 
Naderi et al, 2006; Narita et al, 1998). By incubating mitochondria isolated from SHSY-5Y 
cells with Bax and the compound of interest, we could monitor the ability of the compounds to 
modulate the level of Bax-induced ROS. There were a number of compounds that either 
moderately or significantly lowered Bax-induced ROS but were not specific for Bax (meaning 
they did not competitively bind to Bax in the presence of cy5.5-labelled sdAb5.2). These 
compounds may actually bind to Bax, but not in the same manner as the labelled anti-Bax 
sdAb5.2, thus not dislodging the labelled sdAb in the competitive binding assay, but still 
lowering Bax-induced ROS. Previous work completed by our group suggests that the anti-Bax 
sdAbs may be binding to the VDAC binding site on Bax (specifically the transmembrane, a9 
helix) (Gueorguieva et al, 2006). Perhaps these compounds may not bind directly to the 
transmembrane a9 helix, but could interfere with homodimerization of Bax, or interaction with 
other members of the Bcl-2 family required for translocation of Bax to the mitochondria (such as 
tBid) by binding to the BH3 domain. An alternative theory is that these compounds could be 
protecting the mitochondria in a Bax-independent fashion; for example, by binding to 
components of the mitochondria such as members of the permeability transition pore, thus 
blocking Bax from binding and initiating mitochondrial dysfunction. These compounds could be 
studied further in a cellular model to observe if they offer any protection in vivo. 
There was one compound (compound 25) that elevated Bax-induced mitochondrial ROS. 
This compound could be binding to Bcl-2 protein that is normally associated with the 
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mitochondria, preventing it from sequestering Bax at the mitochondria, thus permitting increased 
amounts of Bax to interact with the mitochondria and causing dysfunction. 
Compound 17 and 22 were the only compounds that were found to competitively bind to Bax 
in the presence of labelled sdAb and lower Bax-induced ROS. However, the competitive 
binding of compound 17 to Bax was very weak, and thus compound 22 was selected to study in 
further detail. Compound 22 was shown to lower Bax-induced ROS in a concentration-
dependent manner and did so at a lower concentration than known anti-oxidant CoQio, although, 
it was important to observe if compound 22 had similar effects inside the cell (in vivo). 
In the future, gel filtration could be performed to see if compound 22 directly interferes 
with either the homodimerization of Bax, heterodimerization of Bax to other members of the 
Bcl-2 family such as Bid, or the Bax-VDAC interaction. Through gel filtration we would be able 
to see first what the elution profile would be for the dimers alone, and then dimers incubated 
with compound 22. The protein dimers would have a higher molecular weight than the proteins 
separately and thus would elute first from the column. If we were to see a decrease in the peak 
associated with the protein dimer, and an appearance of a lower molecular weight peaks, the 
elution volume of these smaller molecular weight peaks could be used to determine the actual 
molecular weight of the protein could give us some indication of the Bax interaction that 
compound 22 is interfering with. 
Since compound 22 is from a targeted library of potential BH3 domain binders, there is a 
possibility that it could target other Bcl-2 family members besides Bax. To analyze other 
potential binders of compound 22, compound 22 could be cross-linked to beads in a column and 
used to pull out potential suspect binding partners such as Bak and Bid. 
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5.8 Specificity and efficacy of compound 22 in preventing oxidative-stress-induced 
apoptosis 
By testing compound 22 on neuronal mammalian cell lines we can monitor its ability to 
halt oxidative-stress-induced apoptosis from inside the cell. As previously mentioned, it was 
important to see if compound 22 could inhibit Bax in vivo in the same manner as was shown in 
vitro. The concentration of compound 22 used in treating the mammalian cell lines was 20uM; 
lOuM and 40uM concentrations were also tried in the beginning, however there was greater 
protection seen using 20uM when compared to lOuM, and 40uM appeared to be slightly toxic to 
the cells when tested on its own (data not shown). Other studies that tested small molecule 
inhibitors of the Bcl-2 family on cellular models have used concentrations in the micromolar 
range. For example, in the study by Degterev et al, concentrations of BH3I-1 that were use in 
the cellular model ranged from 15uM to lOOuM (Degterev et al, 2001). We have also seen in 
our study that there is a diminished absorbance peak of compound 22 incubated in the media 
alone, indicating potential degradation or binding to serum proteins that mask the absorbance 
prior to cellular uptake. 
When cells were monitored five different fields of view were taken of each group, and 
the % viability was averaged between them. In the future, viable/apoptotic cells could be 
quantified via flow cytometry using Annexin V. Post-nuclear cytosolic Caspase 3 levels and 
mitochondrial ROS levels were also lowered by 20uM of compound 22 following treatment to 
levels comparable to untreated control fractions, indicating that compound 22 is indeed exerting 
its effects upstream of mitochondrial dysfunction and subsequent Caspase 3 activation. In the 
future, isolated post-nuclear cytosol and mitochondria should be monitored for purity by 
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checking for the presence of P-actin (in cytosolic fractions) and succinate dehydrogenase (in 
mitochondrial fractions). 
5.9 Preliminary study of the cellular uptake of compound 22 
Through the spectrophotometric analysis of compound 22 in solution, we have 
established a preliminary method of analyzing the cellular uptake of compound 22 from the 
surrounding media. We found that compound 22 has an absorbance peak of 425nm that is 
distinct from both the supplemented media used to grow SHSY-5Y cells, as well as post-nuclear 
cytosolic fractions of SHSY-5Y cells. It was also revealed that perhaps there was some 
degradation of compound 22 in the media over an 18h period or perhaps compound 22 was 
binding to a serum protein present in the media. However, there did appear to be some cellular 
uptake of compound 22 indicated by the lower absorbance at 425nm of compound 22 incubated 
with media and cells, however there could still be further degradation of compound 22. When 
the absorbance spectrum of post nuclear cytosol was taken between 400-500nm, there was very 
minimal absorbance (~0.1) which should be examined further as it is quite surprising that there is 
nothing in the cytosol absorbing in this range. Ideally, compound 22 could be radio-labelled (i.e. 
with 14C) and its presence in subcellular components/organelles could be traced more effectively. 
5.10 Preliminary elucidation of a potential binding site on Bax for compound 22 
Bax permealization of the MOM has been shown to happen through the formation of the 
PTP when Bax binds to the MOM component of the PTP, VDAC (Narita, M et ai, 1998). Since 
we observed that mitochondrial ROS was lowered and AT™ was maintained in cells treated with 
compound 22 (under oxidative stress conditions), we believed that the Bax-VDAC interaction 
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may be prevented in these cells. This theory was evaluated by comparing the level of Bax which 
is co-precipitated with VDAC in control lOOuM H202-treated cells tolOOuM H2O2, compound 
22-treated cells. We found that the level of Bax binding to VDAC was indeed decreased in cells 
treated with compound 22, which suggests that it may be binding to the VDAC binding site on 
Bax (specifically the transmembrane, a9 helix), or binding to the BH3 domain in a manner that 
does not allow a.9 helix to disengage and interact with VDAC. However, this experiment would 
need to be repeated with proper controls in order to be meaningful (thus why the data is not 
shown). Compound 22 could also be interfering with Bax's homerdimerization or its interaction 
with other modulators upstream of MOMP such as Bid (by binding to its BH3 domain). This 
would mean that less Bax translocates to the mitochondria to interact with VDAC, and thus less 
Bax would be pulled down by VDAC. 
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Chapter 6 Conclusions and Future Work 
In this two-part study we were able to identify modulators of two pro-apoptotic proteins 
Caspase 3 and Bax. In the first half of the study we identified anti-Caspase 3 VHHS capable of 
binding to Caspase 3 and either blocking its action (VhhCasp31) or accelerating its activity 
(VhhCasp32). These two VHHs could have applications in the study of cellular mechanisms 
involving Caspase 3 activation as well as in the development of therapeutics for 
neurodegeneration (VhhCasp31) or cancer (VhhCasp32). Importantly, a cell line stably-
expressing the sdAbs would be important in monitoring their behaviour inside the cell. 
The application of the anti-Caspase 3 intrabodies as direct therapeutics against 
neurodegenerative disease and cancer is limited by the difficulty in crossing the blood brain 
barrier. As we have done with the anti-Bax sdAb5.2, the anti-Caspase 3 VHHS could be used in 
screening a pharmacaphore library for small molecular weight compounds that could 
competitively bind to Caspase 3 in the presence of the VHHS as well as modulate the activity of 
Caspase 3 in vitro as well as in vivo. 
In the second half of our study, we screened a small pharmacaphore library for small 
molecular weight compound that could competitively bind to Bax in the presence of a labelled 
anti-Bax sdAb (sdAb5.2) and inhibit the activity of Bax both in vitro and in vivo. We found one 
such compound, compound 22, that was capable of lowering Bax-induced ROS in isolated 
mitochondria, and halted oxidative-stress-induced apoptosis in a neuronal cell model. 
In the future we would like to confirm the preliminary cellular uptake studies and 
potentially have compound 22 radio-labelled to explore its intracellular distribution. 
Additionally, further immunoprecipitations could confirm the role of compound 22 in interfering 
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with Bax-VDAC interactions, and potential interactions with other Bcl-2 family member. 
Currently, our collaborators at the NRC-IBS in Ottawa are engaged in NMR studies looking at 
the potential docking site of compound 22 on Bax. This would aid us in determining with 
greater certainty; the protein-protein interaction compound 22 could be interfering with 
We would also like to study the ability of compound 22 to protect neuronal cells 
following oxidative stress. In this study, we administered compound 22 at the same time as the 
oxidative stress as well as after. It would be interesting to see the effects of compound 22 on 
cells that were first challenged with oxidative stress and then rescued up to 3h following. 
Furthermore, a future goal would be to observe the effects of compound 22 in blocking 
apoptotic cell death in mouse model of ischemia/reperfusion. Mice could be administered 
compound 22 both before and after middle cerebral artery occlusion and subsequent reperfusion, 
and apoptosis could be monitored up to 48h following. This would provide us with further 
insight as to whether compound 22 is well-tolerated within a living organism, and whether it is 
useful as a potential therapeutic in neurodegenerative disease, particularly ischemic stroke. 
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